82 results on '"W. Sulowicz"'
Search Results
2. DIALYSIS CARDIOVASCULAR COMPLICATIONS 1
- Author
-
D. C. Wheeler, S. Abdalla, G. Chertow, P. Parfrey, C. Herzog, I. Mikolasevic, S. Racki, V. Lukenda, S. Milic, B. Devcic, L. Orlic, M. M. Suttorp, T. Hoekstra, G. Ocak, A. T. N. Van Diepen, I. Ott, M. Mittelman, T. J. Rabelink, R. T. Krediet, F. W. Dekker, S. Simone, M. P. S. Dell'Oglio, M. Ciccone, R. Corciulo, G. Castellano, C. Balestra, G. Grandaliano, L. Gesualdo, G. Pertosa, M. Nishida, M. Ando, K. Karasawa, Y. Iwamoto, K. Tsuchiya, K. Nitta, M. Krzanowski, K. Janda, M. Gajda, P. Dumnicka, D. Fedak, G. Lis, P. Ja kowski, J. A. Litwin, W. Su owicz, G. R. Freitas, V. B. Silva, H. Abensur, C. Luders, B. J. Pereira, M. C. Castro, R. B. Oliverira, R. M. Moyses, R. M. Elias, B. C. Silva, H. Tekce, S. Ozturk, G. Aktas, B. Kin Tekce, A. Erdem, M. Ozyasar, T. Taslamacioglu Duman, M. Yazici, A. Kirkpantur, M. M. Balci, A. Turkvatan, B. Afsar, M. Alkis, F. Mandiroglu, L. Voroneanu, D. Siriopol, I. Nistor, M. Apetrii, S. Hogas, M. Onofriescu, A. Covic, W. S. An, S. E. Kim, Y. K. Son, Y. J. Oh, S. Gelev, S. Toshev, L. Trajceska, G. Selim, P. Dzekova, A. Shikole, J. Park, J. S. Lee, E.-S. Shin, S. H. Ann, S.-J. Kim, H. C. Chung, W. Sulowicz, U. Elewa, W. Bichari, K. Abo-Seif, S. Seferi, M. Rroji, E. Likaj, N. Spahia, M. Barbullushi, N. Thereska, C. M. Kopecky, B. Genser, W. Maerz, C. Wanner, M. D. Saemann, T. Weichhart, S. Sezer, B. Gurlek Demirci, E. Tutal, Z. Bal, M. Erkmen Uyar, F. N. Ozdemir Acar, B. Macunluoglu, A. Atakan, E. Ari Bakir, P. Georgianos, P. A. Sarafidis, D. N. Stamatiadis, V. Liakopoulos, P. E. Zebekakis, A. Papagianni, A. N. Lasaridis, N. Eftimovska - Otovic, E. Babalj-Banskolieva, S. Kostadinska-Bogdanoska, R. Grozdanovski, M. Aono, Y. Sato, M. El Amrani, M. Asserraji, M. Benyahia, Y.-K. Lee, S. R. Choi, A. Cho, J.-K. Kim, M.-J. Choi, S. J. Kim, J.-W. Yoon, J.-R. Koo, H. J. Kim, J.-W. Noh, H. Inagaki, N. Yokota, S. Chiyotanda, K. Fukami, S. Fujimoto, Z. Kendi Celebi, S. Kutlay, S. Sengul, G. Nergizoglu, S. Erturk, K. Ates, K. A. Vishnevskii, A. S. Rumyantsev, A. Y. Zemchenkov, A. V. Smirnov, B. Reinhardt, R. Knaup, V. Esteve Simo, J. Carneiro Oliveira, F. Moreno Guzman, M. Fulquet Nicolas, M. Pou Potau, A. Saurina Sole, V. Duarte Gallego, M. Ramirez De Arellano Serna, K. Turkmen, L. Demirtas, E. M. Akbas, E. M. Bakirci, M. Buyuklu, A. Timuroglu, P. I. Georgianos, A. Karpetas, T. Taira, K. Nohtomi, T. Takemura, T. Chiba, T. Hirano, C.-T. Chang, C.-C. Huang, C.-J. Chen, A. Mohamed, H. Kanai, Y. Tamura, Y. Kaizu, A. Kali, O. Yayar, B. Erdogan, B. Eser, Z. Ercan, M. Buyukbakkal, O. Merhametsiz, A. Haspulat, T. Yildirim, B. Bozkurt, M. D. Ayli, D. Gokustun, A. Markaki, M. Grammatikopoulou, G. Fragkiadakis, K. Stylianou, M. Venyhaki, V. Chatzi, O. Stojceva-Taneva, L. Tozija, P. Dzekova-Vidimliski, Z. Petronievic, A. Sikole, V. Moyseyenko, T. Nykula, R. T. Fernandes, D. V. Barreto, G. G. C. Rodrigues, A. Misael, C. T. Branco-Martins, and F. C. Barreto
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,medicine ,Intensive care medicine ,business ,Dialysis (biochemistry) - Published
- 2014
- Full Text
- View/download PDF
3. CLINICAL ACUTE KIDNEY INJURY 2
- Author
-
S. Gonzalez Sanchidrian, C. J. Cebrian Andrada, M. C. Jimenez Herrero, J. L. Deira Lorenzo, P. J. Labrador Gomez, J. P. Marin Alvarez, V. Garcia-Bernalt Funes, S. Gallego Dominguez, I. Castellano Cervino, J. R. Gomez-Martino Arroyo, W. Parapiboon, P. Boonsom, T. Stadler, A. Raddatz, A. Poppleton, W. Hubner, D. Fliser, M. Klingele, J. Rosa, A. Sydor, M. Krzanowski, E. Chowaniec, W. Sulowicz, E. Vidal, C. Mergulhao, H. Pinheiro, L. Sette, G. Amorim, G. Fernandes, L. Valente, F. Ouaddi, I. Tazi, K. Mabrouk, M. Zamd, S. El Khayat, G. Medkouri, M. Benghanem, B. Ramdani, G. Dabo, L. Badaoui, A. Ouled Lahcen, M. Sosqi, L. Marih, A. Chakib, K. Marhoum El Filali, M. J. C. Oliveira, G. Silva Junior, A. M. Sampaio, B. Montenegro, M. P. Alves, G. A. L. Henn, H. A. L. Rocha, G. C. Meneses, A. M. C. Martins, T. R. Sanches, L. C. Andrade, A. C. Seguro, A. B. Liborio, E. F. Daher, M. Haase, B.-P. Robra, J. Hoffmann, B. Isermann, W. Henkel, R. Bellomo, C. Ronco, A. Haase-Fielitz, Y. K. Kee, Y. L. Kim, E. J. Kim, J. T. Park, S. H. Han, T.-H. Yoo, S.-W. Kang, K. H. Choi, H. J. Oh, P. Dharmendra, M. Vinay, M. Mohit, G. Rajesh, A. Dhananjai, B. Pankaj, P. Campos, A. Pires, L. Inchaustegui, S. Avdoshina, S. Villevalde, Z. Kobalava, P. Mukhopadhyay, B. Das, D. Mukherjee, R. Mishra, M. Kar, N. M. Biswas, M. Onuigbo, N. Agbasi, D. Ponce, B. B. Albino, A. L. Balbi, P. Klin, C. Zambrano, L. M. Gutierrez, L. Varela Falcon, F. Zeppa, A. Bilbao, F. Klein, P. Raffaele, K. Y. Chang, H. S. Park, H. W. Kim, B. S. Choi, C. W. Park, C. W. Yang, D. C. Jin, I.-A. Checherita, I. Peride, C. David, D. Radulescu, A. Ciocalteu, A. Niculae, A. Balbi, C. Goes, M. Buffarah, P. Xavier, S. M. Karimi, G. Cserep, D. Gannon, K. Sinnamon, P. Saudan, C. Alves, V. De La Fuente, B. Ponte, S. Carballo, O. Rutschmann, P.-Y. Martin, F. Stucker, A. Saurina, V. Pardo, N. Barba, E. Jovell, M. Pou, V. Esteve, M. Fulquet, V. Duarte, M. Ramirez De Arellano, I. O. Sun, H. J. Yoon, J. G. Kim, K. Y. Lee, K. Tiranathanagul, S. Sallapant, S. Eiam-Ong, S. Treeprasertsuk, I. A. Checherita, B. Geavlete, M. Ando, N. Shingai, T. Morito, K. Ohashi, K. Nitta, D. B. Duarte, L. A. Vanderlei, R. K. A. Bispo, M. E. Pinheiro, H. Si Nga, A. Paes, P. Medeiros, T. M. S. Gentil, L. S. Assis, A. P. Amaral, V. R. C. A. Alvares, K. L. R. S. Scaranello, E. M. D. Soeiro, V. Castanho, I. Castro, S. M. Laranja, S. Barreto, M. Molina, M. Silvisk, B. J. Pereira, A. Izem, D. Amer Mhamed, S. S. El Khayat, C. Donadio, A. Klimenko, M. C. Andreoli, N. K. Souza, A. L. Ammirati, T. N. Matsui, E. L. Naka, F. D. Carneiro, A. C. Ramos, R. K. Lopes, E. S. Dias, M. P. Coelho, R. C. Afonso, B.-H. Ferraz-Neto, M. D. Almeida, M. Durao, M. C. Batista, J. C. Monte, V. G. Pereira, O. P. Santos, B. C. Santos, V. C. Silva, J. G. Raimann, F. B. Nerbass, M. A. Vieira, P. Dabel, A. Richter, J. Callegari, M. Carter, N. W. Levin, J. F. Winchester, P. Kotanko, R. Pecoits-Filho, A. Gjyzari, N. Thereska, M. Barbullushi, A. Koroshi, E. Petrela, S. Mumajesi, J. S. Han, S. Simone, G. Scrascia, E. Montemurno, C. Rotunno, F. Mastro, L. Gesualdo, D. Paparella, G. Pertosa, D. Lopes, C. Santos, C. Cunha, A. M. Gomes, H. Coelho, J. Seabra, A. Qasem, S. Farag, E. Hamed, M. Emara, A. Bihery, H. Pasha, S. Chhaya, G. Mukhopadhyay, C. Das, A. P. F. Vieira, L. L. L. Lima, L. S. Nascimento, A. Zawiasa, M. Ko Odziejska, P. Bia Asiewicz, D. Nowak, and M. Nowicki
- Subjects
Transplantation ,Pathology ,medicine.medical_specialty ,Nephrology ,business.industry ,Acute kidney injury ,medicine ,medicine.disease ,Diffuse alveolar damage ,business - Published
- 2014
- Full Text
- View/download PDF
4. Peritoneal dialysis - A
- Author
-
M. Ito, A. Emami-Naini, N. Keyvandarian, F. Moeinzadeh, M. Mortazavi, S. Taheri, K. Io, T. Nishino, Y. Obata, M. Kitamura, S. Abe, T. Koji, S. Kohno, K. Wakabayashi, C. Hamada, T. Nakano, R. Kanda, H. Io, S. Horikoshi, Y. Tomino, M. R. Korte, N. Braun, S. M. Habib, E. Goffin, A. Summers, L. Heuveling, M. G. H. Betjes, M. Lambie, J. Bankart, D. Johnson, R. Mactier, L. Phillips-Darby, N. Topley, S. Davies, F. X. Liu, R. Leipold, M. Arici, U. Farooqui, K.-h. Cho, J.-y. Do, S.-h. Kang, J.-W. Park, K.-W. Yoon, S.-Y. Jung, C. Sise, P. Rutherford, L. Kovacs, S. Konings, M. Pestana, J. Zimmermann, H. Cramp, D. Stein, K. Bang, J. H. Shin, J. Jeong, J.-H. Kim, N. Matsuo, Y. Maruyama, M. Nakao, Y. Tanno, I. Ohkido, H. Hayakawa, H. Yamamoto, K. Yokoyama, T. Hosoya, F. Iannuzzella, M. Corradini, L. Belloni, A. Stefani, M. Parmeggiani, S. Pasquali, O. Svedberg, P. Stenvinkel, A. R. Qureshi, P. Barany, O. Heimburger, P. Leurs, B. Anderstam, J. Waniewski, S. Antosiewicz, D. Baczynski, M. Galach, Z. Wankowicz, M. Prabhu, S. V. Subhramanyam, K. S. Nayak, J.-C. Hwang, M.-Y. Jiang, Y.-H. Lu, C.-T. Wang, C. Santos, A. Rodriguez-Carmona, M. Perez Fontan, B. Schaefer, S. Macher-Goeppinger, A. Bayazit, P. Sallay, S. Testa, S. Holland-Cunz, U. Querfeld, B. A. Warady, F. Schaefer, C. P. Schmitt, I. Guney, K. Turkmen, R. Yazici, S. Aslan, L. Altintepe, M. Yeksan, I. Kocyigit, M. Sipahioglu, O. Orscelik, A. Unal, A. Celik, S. Abbas, F. Zhu, B. Tokgoz, A. Dogan, O. Oymak, P. Kotanko, N. Levin, M. C. Sanchez-Gonzalez, M. L. Gonzalez-Casaus, E. Gonzalez-Parra, M. Albalate, V. Lorenzo, V. Torregrosa, E. Fernandez, C. de la Piedra, M. Rodriguez, M. Zeiler, T. Monteburini, R. M. Agostinelli, R. Marinelli, S. Santarelli, F. Bermond, C. Bagnis, C. Marcuccio, G. Soragna, M. Bruno, C. Vitale, M. Marangella, F. Martino, E. Scalzotto, M. P. Rodighiero, C. Crepaldi, C. Ronco, S. Seferi, M. Rroji, E. Likaj, M. Barbullushi, N. Thereska, E. J. Kim, J. H. Han, H. M. Koo, F. M. Doh, C. H. Kim, K. I. Ko, M. J. Lee, H. J. Oh, S. H. Han, T.-H. Yoo, K. H. Choi, S.-W. Kang, S. Uzun, S. Karadag, M. Yegen, M. Gursu, S. Ozturk, Z. Aydin, A. Sumnu, E. Cebeci, E. Atalay, R. Kazancioglu, D. Alscher, P. Fritz, J. Latus, M. Kimmel, D. Biegger, M. Lindenmeyer, C. D. Cohen, R. P. Wuthrich, S. Segerer, Y. K. Kim, H. W. Kim, H. C. Song, E. J. Choi, C. W. Yang, A. Matsuda, Y. Tayama, T. Ogawa, M. Iwanaga, S. Okazaki, M. Hatano, T. Kiba, T. Shimizu, H. Hasegawa, T. Mitarai, M. Dratwa, F. Collart, C. Verger, K. Takayanagi, T. Iwashita, C. Noiri, M. Inamura, S. Nakamura, H. Kato, M. H. Sipahioglu, F. Elmali, X. Zhang, J. Ma, A. Giuliani, L. Blanca-Martos, A. Nayak Karopadi, G. Mason, M. T. Santos, I. Fonseca, O. Santos, M. J. Rocha, M. J. Carvalho, A. Cabrita, A. Rodrigues, L. Scabbia, A. Domenici, F. Apponi, M. Tayefeh Jafari, F. Sivo, C. Falcone, G. Punzo, P. Mene, T. Yildirim, R. Yilmaz, A. Azak, M. Altindal, E. Turkmen, B. Altun, M. Duranay, Y. Erdem, M. Buyukbakkal, B. Eser, O. Yayar, Z. Ercan, A. Kali, B. Erdogan, A. Haspulat, O. Merhametsiz, G. Ulusal-Okyay, S. I. Akdag, M. D. Ayli, A. Pietrzycka, P. Miarka, E. Chowaniec, W. Sulowicz, M. Lutwin, M. Gaska, and A. Paciorek
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,medicine.medical_treatment ,Urology ,Medicine ,business ,Peritoneal dialysis - Published
- 2013
- Full Text
- View/download PDF
5. Transplantation: clinical studies - A
- Author
-
T. Yildirim, R. Yilmaz, M. Altindal, E. Turkmen, M. Arici, B. Altun, Y. Erdem, O. Guliyev, M. Erkmen Uyar, E. Tutal, Z. Bal, S. Sezer, U. Bal, B. Say n, B. Erdemir, A. O'Rourke-Potowki, N. Gauge, H. Penny, A. Cronin, S. Frame, D. J. Goldsmith, J. A. Yagan, A. Chandraker, R. M. Velickovic Radovanovic, A. Catic Djordjevic, B. Mitic, N. Stefanovic, T. Cvetkovic, N. Serpieri, F. Grosjean, G. Sileno, M. Torreggiani, V. Esposito, F. Mangione, M. Abelli, F. Castoldi, D. Catucci, C. Esposito, A. Dal Canton, A. V. Vatazin, A. B. Zulkarnaev, C. Borst, Y. Liu, J. Thoning, M. Tepel, C. Libetta, E. Margiotta, I. Borettaz, M. Canevari, C. Martinelli, E. Lainu, F. Meloni, V. Sepe, R. Miguel Costa, E. Vasquez Martul, J. Reboredo, C. Rivera, F. Simonato, G. Tognarelli, G. Daidola, E. Gallo, M. Burdese, V. Cantaluppi, L. Biancone, G. P. Segoloni, M. Priora, M. Messina, M. Tamagnone, A. Linsalata, A. Lavacca, G. Segoloni, W. Zuidema, R. Erdman, J. van de Wetering, F. Dor, J. Roodnat, E. Massey, L. Timmerman, J. IJzermans, W. Weimar, C. Sibley-Allen, R. Hilton, M. Moghul, L. Burnapp, G. Blake, T. Y. Koo, J.-S. Park, H. C. Park, G.-H. Kim, C. H. Lee, I. H. Oh, C. M. Kang, J. K. Hwang, S. C. Park, B. S. Choi, H. J. Chun, J. I. Kim, C. W. Yang, I. S. Moon, S. Van Laecke, W. Van Biesen, E. V. Nagler, Y. Taes, P. Peeters, R. Vanholder, R. Pruthi, R. Ravanan, A. Casula, M. Harber, P. Roderick, D. Fogarty, A. Cho, J.-h. Shin, H. R. Jang, J. E. Lee, W. Huh, D. J. K. Kim, H. Y. Oh, Y.-G. Kim, A. Sancho Calabuig, E. Gavela Martinez, J. Kanter Berga, S. Beltran Catalan, A. I. Avila Bernabeu, L. M. Pallardo Mateu, E. Gonzalez, N. Polanco, M. Molina, E. Gutierrez, L. Garcia Puente, A. Sevillano, E. Morales, M. Praga, A. Andres, M. Banasik, M. Boratynska, K. Koscielska-Kasprzak, D. Bartoszek, M. Myszka, S. Zmonarski, B. Nowakowska, E. Wawrzyniak, A. Halon, P. Chudoba, M. Klinger, J. Rojas-Rivera, J. M. Morales, J. Egido, C. M. Kopecky, M. Haidinger, C. Kaltenecker, M. Antlanger, G. Marsche, M. Holzer, J. Kovarik, J. Werzowa, M. Hecking, M. D. Saemann, J. M. Kim, E. S. Koh, B. H. Chung, Y. S. Kim, M. Krajewska, O. Mazanowska, D. Kaminska, M. Zabinska, B. Malkiewicz, D. Patrzalek, J. Sulowicz, S. Szostek, A. Wojas-Pelc, E. Ignacak, W. Sulowicz, V. Bellizzi, P. Calella, A. Cupisti, A. Capitanini, C. D'Alessandro, D. Giannese, A. Camocardi, G. Conte, M. Barsotti, G. Bilancio, R. Luciani, L. Locsey, I. Seres, D. Kovacs, L. Asztalos, G. Paragh, M. Wohlfahrtova, P. Balaz, S. Rokosny, P. Wohlfahrt, A. Bartonova, O. Viklicky, J. Kers, R. B. Geskus, L. J. Meijer, F. Bemelman, I. J. M. ten Berge, S. Florquin, J.-C. Hwang, M.-Y. Jiang, Y.-H. Lu, S.-F. Weng, A. Testa, G. Porto, M. Sanguedolce, B. Spoto, R. Parlongo, A. Pisano, G. Enia, G. Tripepi, C. Zoccali, N. Mamode, A. Lennerling, F. Citterio, K. Van Assche, S. Sterckx, M. Frunza, H. Jung, A. Pascalev, R. Johnson, C. Loven, T. Soleymanian, H. Keyvani, S. M. Jazayeri, Z. Fazeli, S. Ghamari, M. Mahabadi, V. Chegeni, I. Najafi, M. R. Ganji, K. M. E. Meys, J. W. Groothoff, K. Jager, F. Schaefer, B. Tonshoff, C. Mota, K. Cransberg, K. van Stralen, E. Gurluler, N. Gures, A. Alim, A. Gurkan, U. Cakir, I. Berber, R. Caluwe, E. Nagler, B. Van Vlem, A. Betkowska-Prokop, M. Kuzniewski, M. Krzanowski, I. Masson, M. Flamant, N. Maillard, E. Cavalier, O. Moranne, E. Alamartine, C. Mariat, P. Delanaye, L. L. Canas Sole, E. Iglesias Alvarez, M. C. M. C. Pastor, F. F. Moreno Flores, V. V. Abujder, F. F. Graterol, J. J. Bonet Sol, R. R. Lauzurica Valdemoros, M. Yoshikawa, K. Kitamura, K. Nakai, S. Goto, H. Fujii, T. Ishimura, M. Takeda, M. Fujisawa, S. Nishi, N. Prasad, D. Gurjer, D. Bhadauria, A. Gupta, R. Sharma, A. Kaul, M. Cybulla, M. West, K. Nicholls, J. Torras, G. Sunder-Plassmann, S. Feriozzi, S. Lo, P. Y. H. Wong, D. Ip, C. K. Wong, V. C. C. Chow, S. K. L. Mo, M. Molnar, A. Ujszaszi, M. E. Czira, M. Novak, I. Mucsi, J. M. Cruzado, S. Coelho, N. Porta, O. Bestard, E. Melilli, O. Taco, I. Rivas, J. Grinyo, L.-M. Pouteau, J.-M. N'Guyen, A. Hami, M. Hourmant, N. Ghahramani, Z. Karparvar, S. Shadrou, M. Ghahramani, J. P. Fauvel, A. Hadj-Aissa, F. Buron, E. Morelon, M. Ducher, C. Heine, P. Glander, H.-H. Neumayer, K. Budde, L. Liefeldt, N. Montero, A. C. Webster, A. Royuela, J. Zamora, M. Crespo, J. Pascual, A. Y. Adema, W. T. H. van Dorp, M. J. K. Mallat, H. W. de Fijter, Y. A. Hong, C. W. Park, Y.-S. Kim, G. Suleymanlar, Z. Uzundurukan, A. Kapuagas, I. Sencan, R. Akdag, A. Torio, V. Mas, M. J. Perez-Saez, M. Mir, A. Faura, O. Montes-Ares, M. D. Checa, D. Sawinski, J. Trofe-Clark, T. Sparkes, P. Patel, S. Goral, R. Bloom, H. J. Kim, S. J. Park, T. H. Kim, Y. W. Kim, Y. H. Kim, S. W. Kang, M. Abdel Halim, O. Gheith, T. Al-Otaibi, A. Mosaad, W. Awadeen, T. Said, P. Nair, and M. R. N. Nampoory
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,Medicine ,business ,Intensive care medicine - Published
- 2013
- Full Text
- View/download PDF
6. Peritoneal dialysis
- Author
-
J. Liu, Y. Liu, Y. Xu, X. Zhao, J. Qian, B. Sun, C. Xing, R. Kanda, C. Hamada, T. Nakano, K. Wakabayashi, H. Io, S. Horikoshi, Y. Tomino, N. Ishimatsu, T. Miyamoto, H. Morimoto, J. Nakamata, R. Baba, K. Kanegae, R. Serino, N. Kabashima, Y. Otsuji, Y. Doi, M. Tamura, T. Kusumoto, K. Fukami, S.-I. Yamagishi, S. Ueda, Y. Kaida, T. Hazama, Y. Nakayama, R. Ando, N. Obara, S. Okuda, M. Matsumoto, Y. Furuno, H. Bang-Gee, L. Mazzotta, A. Rosati, A. Carlini, V. T. Henriques, E. Zangiacomi Martinez, J. C. Divino-Filho, R. Pecoits-Filho, J. A. Cardeal Da Costa, T. Gama Axelsson, B. Lindholm, J. J. Carrero, O. Heimburger, P. Stenvinkel, A. R. Qureshi, M. Akazawa, T. Uno, E. Kanda, Y. Maeda, M. Aktsiali, S. Antonopoulou, K. Tsiolaki, N. Bakirtzi, A. Patrinou, M. Georgopoulou, P. Liaveri, N. Afentakis, G. Tsirpanlis, T. Hasegawa, H. Nishiwaki, M. Hirose, D. Komukai, H. Tayama, F. Koiwa, A. Yoshimura, S. L. Lui, S. Lui, S. Yung, C. Tang, F. Ng, W. K. Lo, T. M. Chan, H. M. Koo, F. M. Doh, D. E. Yoo, H. J. Oh, T.-H. Yoo, K. H. Choi, S.-W. Kang, D. S. Han, S. H. Han, N. Fernandes, M. G. Bastos, M. R. Gianotti Franco, A. Chaoubah, M. D. Gloria Lima, S. Kang, J. Do, K. Cho, J. Park, K. Yoon, J.-B. Chen, B.-C. Cheng, T.-C. Chen, Y.-J. Su, C.-H. Wu, Y. Park, J. Jeon, M. Tsikeloudi, P. Pateinakis, K. Patsatsi, E. Manou, D. Sotiriadis, D. Tsakiris, L. Teixeira, A. Rodrigues, M. J. Carvalho, A. Cabrita, D. Mendonca, M. Bruschi, G. Candiano, L. Santucci, S. Luzio, R. Cannavo, G. M. Ghiggeri, E. Verrina, Y. Varadarajan, B. Raju, K.-H. Cho, J.-W. Park, K.-W. Yoon, T.-W. Kim, M. Kimmel, N. Braun, J. Latus, M. D. Alscher, D. Struijk, S. Van Esch, R. T. Krediet, T. Van den Beukel, T. Hoekstra, L. Tirapani, K. De Andrade Bastos, M. Bastos, F. Dekker, T. Yasuhisa, H. Kanai, K. Harada, Y. Kawai, H. Sugiyama, Y. Ito, K. Tsuruya, H. Yoshida, H. Maruyama, S. Goto, M. Nakayama, H. Nakamoto, H. Morinaga, S. Matsuo, H. Makino, M. C. DI Gioia, P. Gallar, N. Laso, I. Rodriguez, G. Cobo, A. Oliet, J. Hynostroza, J. C. Herrero, C. Mon, M. Ortiz, A. Vigil, T. Tomo, J. Portoles, S. Uta, A. M. Tato, P. Lopez-Sanchez, M. Rivera, R. Rodriguez-Pena, G. Del Peso, M. Ortega, C. Felipe, E. Tsampikaki, G. Aperis, A. Kaikis, C. Paliouras, N. Karvouniaris, M. Maragaki, P. Alivanis, B. Kortus-Gotze, T. Hoferhusch, J. Hoyer, F. Martino, M. Kaushik, M. P. Rodighiero, C. Creapldi, C. Ronco, A. Lacquaniti, V. Donato, M. R. Fazio, S. Lucisano, V. Cernaro, R. Lupica, M. Buemi, C. Aloisi, N. Bavbek Ruzgaresen, S. Secilmis, H. Yilmaz, A. Akcay, M. Duranay, N. Akalin, M. R. Altiparmak, S. Trabulus, A. S. Yalin, R. Ataman, K. Serdengecti, K. Schneider, B. Bator, B. Niko, F. Peter, C. Ulmer, L. Joerg, K. Martin, B. Dagmar, O. German, R. Fabian, D. Juergen, S. Stephan, A. Dominik, P. Fritz, B. Rettenmaier, S. Hirschburger, S. Segerer, D. Biegger, T. Lang, G. Ott, M. Habib, M. Korte, M. Hagen, F. Dor, M. Betjes, R. Zietse, C. Scharpf, T. I. Chang, D. H. Shin, D.-S. Han, H. Y. Choi, Y. K. Lee, B. S. Kim, T. H. Yoo, H. C. Park, H. Y. Lee, N. Horimoto, K. Tuji, S. Kitamura, R. Isshiki, M. Iwagami, D. Tsutsumi, Y. Mochida, K. Ishioka, M. Oka, K. Maesato, H. Moriya, T. Ohtake, S. Hidaka, S. Kobayashi, C. Higuchi, Y. Tanihata, M. Ishii, H. Sugimoto, N. Sato, A. Kyono, T. Ogawa, H. Nishimura, K. Otsuka, J.-Y. Do, C. Du Halgouet, A. Latifa, V. Anne Sophie, D. Emmanuel, R. Christine, V. Francois, T. Grzelak, L. Czyzewska-Majchrzak, M. Kramkowska, H. Witmanowski, K. Czyzewska, K. Janda, M. Krzanowski, P. Dumnicka, W. Sulowicz, M. Rroji, S. Seferi, M. Barbullushi, E. Likaj, E. Petrela, N. Thereska, G. Cabiddu, E. Dessi, A. Arceri, P. Laura, E. Manca, M. Conti, R. Cao, A. Pani, C.-T. Liao, O. Vega Vega, A. Mendoza de la Garza, R. Correa-Rotter, A. Ueda, K. Nagai, M. Morimoto, A. Hirayama, S. Owada, Y. Tonozuka, C. Saito, K. Yamagata, A. Matsuda, Y. Tayama, M. Iwanaga, C. Noiri, M. Hatano, T. Kiba, K. Kanozawa, H. Katou, H. Hasegawa, T. Mitarai, S. Ros-Ruiz, L. Fuentes-Sanchez, C. Jironda-Gallegos, E. Gutierrez-Vilches, P. Garcia-Frias, D. Hernandez-Marrero, S. Lee, X. Lai, W. Chen, Z. Guo, M. Braide, V. Cristina, S. G. Popa, M. Maria, M. Eugen, P. DI Loreto, N. Spahia, L. O. Sanchez Macias, K. I. Lares Castellanos, J. A. Hernandez Pacheco, R. Correa Rotter, A. Pedro Ventura, S. Olivia, V. Joana, F. Francisco, C. Maria Joao, C. Antonio, A. S. Rodrigues, N. Atas, Y. Erten, K. Onec, S. Inal, S. Topal, A. Akyel, B. Celik, G. U. Okyay, Y. Tavil, M. Zeiler, T. Monteburini, R. M. Agostinelli, R. Marinelli, S. Santarelli, C. Yaylaci, G. Sahin, G. Guz, S. Sindel, A. Pinho, A. Malho Guedes, A. Fragoso, H. Carreira, I. Pinto, I. Bernardo, P. Leao, B. Kusnierz-Cabala, A. Krasniak, E. Chowaniec, B. Tabor-Ciepiela, K. Turkmen, O. Ozbek, M. Kayrak, C. Samur, I. Guler, H. Z. Tonbul, K. Rusai, R. Herzog, K. Kratochwill, L. Kuster, C. Aufricht, C.-M. Meier, D. Fliser, M. K. Schilling, M. Klingele, M. Fukasawa, M. Takeda, M. Kamiyama, Y. R. Song, H. J. Kim, S. G. Kim, J.-K. Kim, J. W. Noh, J. W. Yoon, and J.-R. Koo
- Subjects
Transplantation ,Nephrology - Published
- 2012
- Full Text
- View/download PDF
7. Mineral and bone disease - CKD 5D
- Author
-
M. Hecking, A. Kainz, B. Bielesz, M. Plischke, G. Beilhack, W. H. Hoerl, G. Sunder-Plassmann, C. Bieglmayer, S. Benchetrit, J. Green, J. Bernheim, E. Golan, N. Oyake, K. Suzuki, S. Itoh, K. Tanabe, A. Fujimori, S. Okada, K. Yamamoto, M. Sakai, N. Kamiura, P. Solenne, F. Guebre-Egziabher, J. Bacchetta, J. Drai, M. Richard, R. Chapurlat, D. Fouque, Z. Nowak, K. Grzegorz, K. Maria, W. Zofia, K. Zamboch, J. Zahalkova, Z. Kosatikova, P. Skypalova, J. Skarda, J. Cunha, M. Boim, V. Ferreira, M. Naves, H. Kikuchi, H. Shimada, Y. Takimoto, R. Karasawa, M. Shimotori, K. Ikarashi, N. Saito, S. Miyazaki, S. Sakai, M. Suzuki, H. Ogata, A. Takeshima, M. Yamamoto, K. Asakura, T. Kato, K. Shishido, F. Koiwa, M. Mizobuchi, E. Kinugasa, T. Akizawa, F. Londrino, V. Corbani, M. Ardini, V. Falqui, T. Zattera, G. Rombola', Y. Takeshige, K. Matsuzaka, P. Ciceri, E. Volpi, I. Brenna, F. Elli, E. Borghi, D. Brancaccio, M. Cozzolino, K. Farrand, J. B. Copley, J. Heise, M. Fridman, M. Keith, A. Silverberg, R. Wilson, L. Poole, G. Jean, E. Bresson, C. Chazot, F. Maduell, M. Arias, A. Sentis, N. Rodriguez, S. Jimenez, B. Alemany, N. Perez, M. Vera, N. Fontsere, M. Carrera, A. Cases, M. Sonikian, T. Miha, I. Skarakis, I. Karatzas, A. Karaitianou, V. Tomanoski, D. Petkovic, I. Curic, R. Hrvacevic, N. Kaperonis, C. Kourvelou, A. Sgantzos, D. Nastou, G. Ntatsis, S. Ziakka, F. Karakasis, V. Nikolopoulos, D. Zoubaniotou, A. Koutsovasili, A. Zagorianakos, V. Kolovos, N. Papagalanis, V. Forni, M. Pruijm, E. Tousset, C. Zweiacker, I. Menetrey, L. Berwert, R. Bullani, A. Cherpillod, L. Gabutti, T. Gauthier, G. Halabi, C. Mathieu, P. Meier, O. Phan, S. Pianca, C. Schoenholzer, D. Teta, B. Von Albertini, B. Vrijens, M. Burnier, N. Kurita, M. Fukagawa, Y. Onishi, T. Yamaguchi, T. Hasegawa, S. Fukuma, K. Kurokawa, S. Fukuhara, P. Urena, I. Bridges, C. Christiano, S. Cournoyer, K. Cooper, M. Farouk, N. Kopyt, M. Rodriguez, D. Zehnder, A. Covic, Y. Tominaga, T. Hiramitsu, T. Yamamoto, K. Nanmoku, Y. Matsuda, T. Tsuzuki, C.-L. Lang, K.-C. Lu, M.-H. Wang, S.-Y. Liu, J.-W. Huang, C.-K. Chiang, K.-Y. Hung, C. Bantis, N.-M. Kouri, E. Tsandekidou, S. Frangidis, A. Tsiandoulas, E. Liakou, G. Bamichas, M. Stangou, A. Papagianni, G. Efstratiadis, T. Natse, D. Memmos, P. Messa, G. Cannella, S. Mazzaferro, X. Yu, B. Bieber, M. Guidinger, X. Yang, F. Tentori, R. Pisoni, J. Qian, N. Chen, Y. Yan, M. Wang, L. Zuo, H. Wang, J. Albert, S. Ramirez, F. Caccetta, M. Caroppo, F. Musio, A. Mudoni, A. Accogli, M. D. Zacheo, V. Nuzzo, G. Selim, O. Stojceva-Taneva, L. Tozija, S. Gelev, V. Pusevski, P. Dzekova-Vidimliski, I. Rambabova-Busletic, A. Sikole, P. Esposito, R. Coppo, F. Malberti, A. Dal Canton, K. Moriwaki, H. Komaba, T. Kakuta, V. Cernaro, R. Lupica, V. Donato, A. Lacquaniti, M. R. Fazio, S. Lucisano, M. Buemi, S. Okuno, E. Ishimura, N. Tsuboniwa, K. Norimine, K. Yamakawa, T. Yamakawa, S. Shoji, K. Mori, Y. Nishizawa, M. Inaba, M. Dahaba, S. Seck, M. Cisse, Y. Jotoku, Y. Sato, N. Dimkovic, E. Asicioglu, A. Kahveci, H. Arikan, M. Koc, S. Tuglular, C. Ozener, R. Kido, T. Yamaguch, A. Krasniak, M. Drozdz, G. Chmiel, P. Podolec, M. Pasowicz, M. Kowalczyk-Michalek, W. Sulowicz, G. Perez-Suarez, E. Baamonde, E. Bosch, J. I. Ramirez, B. El Hayek, M. D. M. Lago, C. Garcia, M. D. Checa, R. Hiramatsu, Y. Ubara, K. Salas, E. S. Vicent, J. C. Gonzalez Oliva, M. Fulquet, V. Duarte, M. Pou, A. Saurina, J. Macias, M. Ramirez de Arellano, P. Matias, C. Jorge, M. Mendes, T. Amaral, C. Ferreira, I. Aires, C. Gil, A. Ferreira, C. Arcal, J. M. Campistol, S. Seferi, M. Rroji, E. Likaj, E. Petrela, M. Barbullushi, N. Zeneli, S. Mumajesi, N. Thereska, C. Vulpio, M. Bossola, E. Stigliano, G. Fadda, A. P. S. Gueiros, J. O. Borba Junior, A. B. d. M. D. S. Lordsllen, J. E. d. B. Gueiros, N. Itami, K. Tuneyama, S. Uemura, H. Hamada, J. Takada, K. Takahashi, K. Adamidis, T. Apostolou, C. Pleros, T. Oikonomaki, E. Kyratzi, D. Exarchos, G. Metaxatos, S. Dracopoulos, N. Nikolopoulou, P. Delanaye, B. Dubois, J.-M. Krzesinski, E. Cavalier, V. De la Fuente, M. T. Gil, P. Gutierrez, P. Delgado, J. Ribero, L. Arenas, S. Sezer, E. Tutal, Z. Bal, M. Erkmen Uyar, F. N. Ozdemir Acar, R. Azevedo de Oliveira, F. Carvalho Barreto, L. Dos Reis, J. Cunha Ferreira, Z. Maria Leme Britto, R. Maria Moyses, V. Jorgetti, R. Ozelsancak, B. Gurlek Demirci, D. Torun, L. Veljancic, M. Radojevic, Z. Paunic, N. Vavic, K. Obrencevic, Z. Kovacevic, and J. Pejovic
- Subjects
Transplantation ,Nephrology - Published
- 2012
- Full Text
- View/download PDF
8. Cardiovascular complications in CKD 5D
- Author
-
M. Fusaro, M. Noale, G. Tripepi, A. D'angelo, D. Miozzo, M. Gallieni, P.-V. Study Group, M. Tsamelesvili, C. Dimitriadis, A. Papagianni, C. Raidis, G. Efstratiadis, D. Memmos, R. Mutluay, C. Konca Degertekin, U. Derici, S. M. Deger, F. Akkiyal, S. Gultekin, S. Gonen, G. Tacoy, T. Arinsoy, S. Sindel, C. Sanchez-Perales, E. Vazquez, E. Merino, P. Perez Del Barrio, F. J. Borrego, M. J. Borrego, A. Liebana, M. Krzanowski, K. Janda, P. Dumnicka, A. Krasniak, W. Sulowicz, Y.-O. Kim, S.-A. Yoon, Y.-S. Yun, H.-C. Song, B.-S. Kim, M. A. Cheong, A. Pasch, S. Farese, J. Floege, W. Jahnen-Dechent, T. Ohtake, R. Furuya, M. Iwagami, D. Tsutsumi, Y. Mochida, K. Ishioka, M. Oka, K. Maesato, H. Moriya, S. Hidaka, S. Kobayashi, A. Guedes, A. Malho Guedes, A. Pinho, A. Fragoso, A. Cruz, P. Mendes, E. Morgado, I. Bexiga, A. P. Silva, P. Neves, N. Oyake, K. Suzuki, S. Itoh, S. Yano, K. Turkmen, H. Kayikcioglu, O. Ozbek, M. Saglam, A. Toker, H. Z. Tonbul, S. Gelev, L. Trajceska, E. Srbinovska, S. Pavleska, V. Amitov, G. Selim, P. Dzekova, A. Sikole, H. Bouarich, S. Lopez, C. Alvarez, I. Arribas, P. DE Sequera, D. Rodriguez, S. Tanaka, T. Kanemitsu, M. Sugahara, M. Kobayashi, L. Uchida, Y. Ishimoto, N. Kotera, S. Tanimoto, K. Tanabe, K. Hara, T. Sugimoto, N. Mise, B. Goldstein, M. Turakhia, C. Arce, W. Winkelmayer, B. E.-D. Zayed, K. Said, M. Nishimura, Y. Okamoto, T. Tokoro, M. Nishida, T. Hashimoto, N. Iwamoto, H. Takahashi, T. Ono, N. Sato, J. Raimann, L. A. Usvyat, J. Sands, N. W. Levin, P. Kotanko, M. Iwasaki, N. Joki, Y. Tanaka, N. Ikeda, T. Hayashi, S. Kubo, T.-A. Imamura, Y. Takahashi, K. Hirahata, Y. Imamura, H. Hase, K. Claes, B. Meijers, B. Bammens, D. Kuypers, M. Naesens, Y. Vanrenterghem, P. Evenepoel, G. Boscutti, L. Calabresi, M. Bosco, S. Simonelli, E. Boer, C. Vitali, M. Martone, P. L. Mattei, G. Franceschini, E. Baligh, E. El-Shafey, A. Ezaat, A. Zawada, K. Rogacev, B. Hummel, O. Grun, A. Friedrich, B. Rotter, P. Winter, J. Geisel, D. Fliser, G. H. Heine, J.-I. Makino, K.-S. Makino, T. Ito, S. Genovesi, A. Santoro, P. Fabbrini, E. Rossi, D. Pogliani, A. Stella, G. Bonforte, G. Remuzzi, S. Bertoli, C. Pozzi, S. Pasquali, L. Cagnoli, F. Conte, I. Buzadzic, J. Tosic, N. Dimkovic, Z. Djuric, J. Popovic, I. Pejin Grubisa, N. Barjaktarevic, A. DI Napoli, D. DI Lallo, M. F. Salvatori, F. Franco, S. Chicca, G. Guasticchi, M. Onofriescu, S. Hogas, V. Luminita, A. Mugurel, V. Gabriel, F. Laura, M. Irina, C. Adrian, E. Bosch, E. Baamonde, C. Culebras, G. Perez, B. El Hayek, J. I. Ramirez, A. Ramirez, C. Garcia, M. Lago, A. Toledo, M. D. Checa, T. Taira, T. Hirano, K. Nohtomi, T. Hyodo, T. Chiba, A. Saito, Y. K. Kim, E. J. Choi, C. W. Yang, Y.-S. Kim, P. S. Lim, W. Ming Ying, J. Ya-Chung, I. Zaripova, I. Kayukov, A. Essaian, A. Nimgirova, H. Young, M. Dungey, E. L. Watson, R. Baines, J. O. Burton, A. C. Smith, K. Yamazaki, M. Bossola, L. Colacicco, D. Scribano, C. Vulpio, L. Tazza, T. Okada, N. Okada, I. Michibata, T. Yura, N. Montero, M. Soler, M. Pascual, C. Barrios, E. Marquez, E. Rodriguez, M. A. Orfila, H. Cao, E. Arcos, J. Comas, J. Pascual, M. Ferrario, F. Garzotto, T. Sironi, S. Monacizzo, F. Basso, D. N. Cruz, U. Moissl, C. Tetta, M. G. Signorini, S. Cerutti, C. Ronco, I. Mostovaya, M. Grooteman, M. Van den Dorpel, L. Penne, N. Van der Weerd, A. Mazairac, C. Den Hoedt, R. Levesque, M. Nube, P. Ter Wee, M. Bots, P. Blankestijn, J. Liu, K. L. MA, X. Zhang, B. C. Liu, I.-D. Vladu, R. Mustafa, D. Cana-Ruiu, C. Vaduva, C. Grauntanu, E. Mota, R. Singh, N. Abbasian, C. Stover, N. Brunskill, J. Burton, K. Herbert, A. Bevington, M. Wu, R.-N. Tang, M. Gao, H. Liu, L. Chen, L.-L. LV, B.-C. Liu, M. Nikodimopoulou, S. Liakos, S. Kapoulas, C. Karvounis, D. Fedak, M. Kuzniewski, D. Paulina, B. Kusnierz-Cabala, M. Kapusta, B. Solnica, A. Junque, E. S. Vicent, L. Moreno, M. Fulquet, V. Duarte, A. Saurina, M. Pou, J. Macias, M. Lavado, M. Ramirez de Arellano, M. Ryuzaki, H. Nakamoto, S. Kinoshita, E. Kobayashi, C. Takimoto, T. Shishido, G. Enia, C. Torino, R. Tripepi, V. Panuccio, M. Postorino, A. Clementi, M. Garozzo, G. Bonanno, R. Boito, G. Natale, T. Cicchetti, A. Chippari, D. Logozzo, G. Alati, S. Cassani, A. Sellaro, C. Zoccali, B. Quiroga, E. Verde, S. Abad, A. Vega, M. Goicoechea, J. Reque, J. M. Lopez-Gomez, J. Luno, C. Cabre Menendez, V. Moles, J. P. Vives, D. Villa, J. Vinas, T. Compte, M. Arruche, C. Diaz, J. Soler, J. Aguilera, A. Martinez Vea, A. De Mauri, P. David, M. M. Conte, D. Chiarinotti, C. E. Ruva, M. De Leo, A.-S. Bargnoux, M. Morena, I. Jaussent, L. Chalabi, P. Bories, J.-J. Dion, P. Henri, M. Delage, A.-M. Dupuy, S. Badiou, B. Canaud, J.-P. Cristol, E. Sironi, F. Pieruzzi, E. Galbiati, M. R. Vigano, S. Anpalakhan, S. Rocha, N. Chitalia, R. Sharma, J. C. Kaski, J. Chambers, D. Goldsmith, D. Banerjee, V. Cernaro, A. Lacquaniti, R. Lupica, S. Lucisano, M. R. Fazio, V. Donato, M. Buemi, I. Segalen, U. Vinsonneau, T. Tanquerel, G. Quiniou, Y. Le Meur, E. Seibert, M. Girndt, K. Zohles, C. Ulrich, A. Kluttig, S. Nuding, C. Swenne, J. Kors, K. Werdan, R. Fiedler, N. C. Van der Weerd, M. P. Grooteman, M. A. Van den Dorpel, M. J. Nube, J. Wetzels, D. W. Swinkels, P. M. Ter Wee, A. Khandekar, J. Khandge, J. E. Lee, S. J. Moon, K. H. Choi, H. Y. Lee, B. S. Kim, E. Tuaillon, A. Rodriguez, L. Chenine, J.-P. Vendrell, Y.-M. Sue, C.-H. Tang, Y.-C. Chen, P. Segura, M. J. Garcia Cortes, J. M. Gil, M. M. Biechy, D. Poulikakos, A. Shah, M. Persson, P. Dattolo, M. Amidone, S. Michelassi, L. Moriconi, G. Betti, P. Conti, A. Rosati, A. Mannarino, V. Panichi, F. Pizzarelli, K. Klejna, B. Naumnik, E. Koc-Zorawska, M. Mysliwiec, S. Dimitrie, H. Simona, O. Mihaela, O. Gabriela, S. Radu, P. Octavian, H. Akdam, H. Akar, Y. Yenicerioglu, O. Kucuk, I. Kurt Omurlu, S. Thambiah, R. Roplekar, P. Manghat, I. Fogelman, W. Fraser, G. Hampson, E. Likaj, G. Caco, S. Seferi, M. Rroji, M. Barbullushi, N. Thereska, A. Serban, V. Carmen, S. Cristian, L. Silvia, and A. Covic
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,medicine ,Intensive care medicine ,business - Published
- 2012
- Full Text
- View/download PDF
9. Pathogenesis and treatment of dialysis hypotension
- Author
-
W Sulowicz and A Radziszewski
- Subjects
Nephrology ,medicine.medical_specialty ,education.field_of_study ,business.industry ,medicine.medical_treatment ,Midodrine ,Population ,medicine.disease ,Internal medicine ,Hypovolemia ,Heart failure ,medicine ,Intravascular volume status ,Renal replacement therapy ,Hemodialysis ,medicine.symptom ,Intensive care medicine ,business ,education ,medicine.drug - Abstract
Dialysis-induced hypotension (DIH) is a very serious clinical problem. It is one of the most frequent complication in renal replacement therapy which diminish patient's quality of life, and increases mortality in the dialyzed population. The main mechanism of DIH is rapid reduction of blood volume owing to ultrafiltration and decrease in extracellular osmolarity during the dialysis session. Coexisting illnesses, especially cardiovascular diseases, particularly common in older and diabetic patients have an essential meaning in the episodes of dialytic hypotension. Efficient treatment of DIH is difficult owing to no generally accepted guidelines – is still a great challenge to the nephrologist. Multilevel strategy of DIH management includes emergency replacement of intravascular volume in acute episodes of hypotonia, accurate assessment of ‘dry weight', education of the patient, adequate hypertension treatment, and assessment methods strictly related to hemodialysis procedure such as low dialysate temperature, longer dialysis sessions or daily dialysis, sodium profiling or application of the modern dialysis technique as biofeedback equipment. There is also a possibility for pharmacological treatment with the use of such agents – as the well described midodrine, or other drugs such as caffeine, effedrin, and vasopressin analogs. The new class of drugs which can be a novel therapeutic option for DIH treatment are adenosine receptor antagonists and selective inhibitors of the inducible form of nitric oxide synthase. Besides the discussed strategies, efficient treatment of congestive heart failure, a common reason of hypotension in uremic patients, should not be overlooked.
- Published
- 2006
- Full Text
- View/download PDF
10. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study
- Author
-
Marian Klinger, F. Metivier, D. Oguey, Frank C. Dougherty, A. L. M. De Francisco, V. Vargemezis, S. Niemczyk, and W. Sulowicz
- Subjects
Adult ,Male ,medicine.medical_specialty ,Randomization ,Anemia ,Phases of clinical research ,Gastroenterology ,Polyethylene Glycols ,law.invention ,Hemoglobins ,Randomized controlled trial ,Renal Dialysis ,law ,Internal medicine ,Humans ,Medicine ,Erythropoietin ,Aged ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Recombinant Proteins ,Surgery ,Continuous erythropoietin receptor activator ,Clinical trial ,Treatment Outcome ,Kidney Failure, Chronic ,Female ,business ,Kidney disease ,medicine.drug - Abstract
This dose-finding, open-label study examined the potential of subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) to correct anaemia at extended administration intervals in 61 erythropoiesis-stimulating agent-naive patients with chronic kidney disease (CKD) on dialysis. After a 4-week run-in, patients were randomised to C.E.R.A. 0.15, 0.30 and 0.45 microg/kg/week. Within these dose groups, patients were further randomised to once weekly, once every 2 weeks or once every 3 weeks treatment. Mean changes in haemoglobin (Hb) increased with increasing C.E.R.A. dose during a period of 6 weeks where no dose adjustments were permitted. The effect was independent of administration schedule. Erythropoietic responses were sustained until the end of the study (12 weeks) in all groups. In total, 90% of patients in the 0.30 microg/kg/week group and 79% in the 0.45 microg/kg/week group responded to treatment (Hb increase > or =1.0 g/dl), compared with 72% in the 0.15 microg/kg/week group. Faster median response time was associated with increasing dose (51, 38 and 31 days, respectively) and response was unrelated to administration frequency. C.E.R.A. was generally well tolerated. Our results suggest that 0.60 microg/kg twice monthly would be a suitable starting dose of C.E.R.A. for the initiation of anaemia correction in patients with CKD on dialysis. Phase III studies will confirm the feasibility of using C.E.R.A. at extended administration intervals in patients with CKD and anaemia.
- Published
- 2006
- Full Text
- View/download PDF
11. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial
- Author
-
P. Ryckelynck, Y. Woredekal, T. Gehr, Marian Klinger, J. Passauer, K. Liss, E. Del Valle, B. Linares, Ferdinando Avella, Stolear Jc, S. Tolkan, O. Hermida, V. Wizemann, Ricardo Correa-Rotter, J. Santos, Gert Mayer, Michael Anger, B. Pellegrino, B. Wikström, A. Ståhl, H. Al-Bander, Pedro Alejandro Gordan, Philip A. Kalra, E. Galindo-Ramos, Carmine Zoccali, G. Dolson, M. Eigner, Sanjay Dalal, G. Touchard, J Peeters, G. Da Roza, Shannon Murphy, R. Errico, M. Lonergan, A. Andrusev, H. Boulechfar, P. Zaoui, Michael Suranyi, de Francisco Martín de Francisco, S. Jacobson, B. Gupta, C. Stafford, J. Picollo de Oliveira, Ilka Regina Souza de Oliveira, F. Dumler, J. Martinez Saye, E. de Almeida Romão, Emmanuel A. Burdmann, C. Vermeij, N. Kumar, E. Shahmir, J. Stratton, R. Schmidt, Mario Cozzolino, Lars Christian Rump, Rainer Oberbauer, J. Kumar, M. Saklayen, Brian Hutchison, C. Denu-Ciocca, L. Weiss, E. Friedman, L. Renders, K. Gurevich, L. Brandi, W. Shapiro, Kym M. Bannister, K. Berta, Muhammad M. Yaqoob, C. Lok, A. Pedrosa, Rosa M.A. Moysés, K. Bhandari, J. Arrieta, T. Crouch, Brigitte Maes, G. Wong, Myriam González, Matthew R. P. Davies, R. Gonzalez, Geoffrey A. Block, T. Nammour, T. Youell, J. Ramirez, S. Tobe, N. Ramirez, T. Bochicchio-Ricardelli, J. Cangiano-Rivera, D. Streja, J. Endsley, K. Ang, R. Patak, J. Cheng, T. Rogers, Alberto Albertazzi, H. Holzer, G. Choukroun, Jose A.L. Arruda, Philippe Rieu, P. Simon, Stephen Z. Fadem, Jared G. Sugihara, H. Alfred, Bruce F. Culleton, G. Frascà, Giovanni Pertosa, W. Van Kuijk, H. Beresan, Samuel S. Blumenthal, Piergiorgio Messa, H. Baer, Michael C. Braun, B. Rutkowski, W. Riegel, M. Komandenko, V. Ermolenko, Martin Wilkie, N. Muirhead, Peter G. Kerr, D. Rattensberger, J. Sabto, Anjay Rastogi, L. Lef, M. El Shahawy, D. Tharpe, A. Smirnov, J. Pons, F. García, F. Zantvoort, A. Lionet, J. Topf, Marcia R. Silver, Reinhard Kramar, E. Moriero, A. Rekhi, S. Roe, P. Batista, E. Kolmakova, F. Rahim, M. Ostrowski, Janice P. Lea, Patrizia Ondei, C. Martinez, J. Donck, Nicole Lopez, F. Schena, Allen R. Nissenson, Alex P.S. Disney, R. Valtuille, C. Najun Zarazaga, M. Fraenkel, Pieter Evenepoel, R. Cottiero, S. Di Giulio, V. Gura, S. Karunakaran, P. Nader, F. Saldanha Thome, Walter Douthat, A. Fekete, L. Arbeit, W. Sulowicz, I. Marin, Charles R.V. Tomson, Andrzej Wiecek, Luis A. Juncos, G. Mingardi, P. Light, Max Dratwa, H. Reichel, R. Raja, U. Ranjit, G. Sterner, E. Coll Piera, P. Pai, Robert J. Walker, R. Bregman, E. Hübel, M. Timofeev, T. Szabo, A. Elli, N. Padmanabhan, N. Garrote, M. Mysliwiec, David C. Wheeler, J. Cruz-Valdez, R. Klauser, Maree-Ross Smith, Antonio Carlos Carvalho, A. Losito, M. Durlik, G. Petraglia, Gianni Cappelli, Y. Lien, M. Chaffin, N. García, R. Halligan, Glenn M. Chertow, M. Bastos, P. Smak Gregoor, S. Ong, M. Belledonne, Fredric O. Finkelstein, J. Martínez García, R. Pecoits Filho, M. Klingberg, B. Carvalho, S. Noble, T. Plumb, A. Chew Wong, Michael Roppolo, U. Neyer, S. Ahmad, J. Mackie, R. Minasian, M. Verrelli, A. Abukurah, M. Laski, P. Brunet, Madeleine V. Pahl, Daniel Zehnder, E. Alas, Muralidhar Acharya, G. Rudolf, G. Zakar, M. Reddy, R. Specter, G. Grandaliano, I. Kulcsar, A. Amatya, Eugenie Pedagogos, O. Ayodeji, G. Jensen, S. Diamond, Xavier Warling, P. Teredesai, M. Mathew, M. Haque, M. Solis, E. Andrés Ribes, M.A. van den Dorpel, Akhtar Ashfaq, Christian Rabbat, David G. Warnock, M. Sebastian Diaz, C. Mousson, R. Darwish, M. Sperto Baptista, N. Salgado, E. Alvarez Sandoval, M. Vasilevsky, P. Chidester, D. Polack, Simon J. Davies, G. Brosnahan, A. Agarwal, Chaim Charytan, T. Hannedouche, M. Gross, I. Arias, G. James, Jürgen Floege, Tom Dejagere, Patrick S. Parfrey, S. Cournoyer, T. Cavalieri, Gérard M. London, K. Gandhi, A. Kshirsagar, O. Khrustalev, J. Zacharias, Michel Dhaene, Jennifer Tuazon, W. Weise, J. Guzman-Rivera, HS Brink, Alastair J. Hutchison, P. D. Cunha, Robyn G Langham, S. Soman, J. Goldman, S. Kazup Erdelyine, A. Widerhorn, M. Henriquez, N. Hunt, W. Hoerl, O. Arkossy, J. Szegedi, R. Dhingra, M. Fernandez Lucas, Jesus Navarro, A. Kark, Andrey Gurevich, Cynthia J. Brown, Rajnish Mehrotra, L. Kleinman, S. Ferenczi, Loreto Gesualdo, V. Schwenger, M. Ramirez, N. Mittman, Ana María Cusumano, K. Marczewski, Moustafa Moustafa, Sônia M. H. A. Araújo, E. Ladanyi, M. Auricchio, Maurice Laville, P. Urena Torres, C. Gallart, A. Israelit, V. Altobelli, E. Hagen, S. Nosrati, John P. Middleton, Kant Ks, F. Al-Saghir, S. Steinberg, S. Neiva Coelho, Botond Csiky, Philip G Zager, M. Sekkarie, Vanda Jorgetti, Domingos O. d'Avila, Carol A. Pollock, L. Lai, B. von Albertini, Beckie Michael, U. Kunzendorf, N. Frischmuth, A. Durrbach, L. Vasconcellos, Raymond Vanholder, M. Dickenmann, B. Schiller-Moran, Steven D. Soroka, J. Rubin, O. Balkarova, S. Morse, M. Teixeira Araújo, D. Perlin, M. Khan, C. Hura, Dagmar-C. Fischer, D. Machado, Seamas C. Donnelly, D. Sapir, V. Lorica, L. Deboni, M. Jose, M. Galicia, K. Bidas, David Spiegel, David Goldsmith, Peter F Mount, A. Strokov, L. Yu, J. Pitone, Biagio Ricciardi, Alastair Gillies, M. Moyses Neto, Piergiorgio Bolasco, V. Anashkin, John R. Sedor, M. Lee, E.M. Jones, M. Culpepper, G. London, D. Joly, N. Khadikova, Charles A. Herzog, P. Meier, M. Farina, Dana V. Rizk, William M. McClellan, M. Cook, Bastian Dehmel, Patrizia Ferrari, F. Almeida, V. Pogue, R. McCrary, F. Macario, J. Golden, E. Wijeyesinghe, Tilman B. Drüeke, E. Osanloo, M. Muszytowski, F. Arif, Giuseppe Villa, M. Torres Zamora, Steven Zeig, N. Thompson, A. Jamal, C. Sholer, P. Stroumza, D. Reddan, Arun Gupta, J. Montenegro, T. DelGiorno, D. Eadington, G. Shostka, Michel Jadoul, A. Weigert, Sergio Stefoni, P. Dreyer, Carmel M. Hawley, J. Cardeal da Costa, M. Switalski, G. Talaulikar, A. Felsenfeld, J. MacLaurin, T. Herman, N. Pritchard, M. Michaud, K.-U. Eckardt, R. Romero, G. Volgina, Fred E. Husserl, J. Soler Amigó, David S. Goldfarb, A. Matalon, M. D. Torres, P. Sampaio Lacativa, L. Major, U. Lund, A. Lafalla, S. Sarkar, Jennifer M. MacRae, J. Lobo, Liudmila Rozhinskaya, Johann Braun, H. Daugaard, S. Khokhar, S. Rubinstein, D. Bhatia, G. Timokhovskaya, T. Wooldridge, A. Voßkühler, Nelson Kopyt, Pablo E. Pergola, Michel Burnier, L. Samuels, J. Alcázar de La Ossa, J. Billiouw, R. Liebl, P. Sidhu, S. Menahem, P. Montambault, E. Schwertfeger, K. Staroselsky, J. Kovarik, S. Horn, N. Tareen, Simon D. Roger, Francesco Locatelli, Kenneth W. Mahaffey, J Vanwalleghem, Robert I. Lynn, M. Prados, K. Kapatkin, N. Peñalba, Kailash Jindal, M. Stegman, R. Stahl, Joseph A. Eustace, S. Desmeules, A. Hazzan, D. Scott, B. Taparia, G. Keightley, P. Jensen, V. Ortalda, K. McConnell, Alejandro Martin-Malo, Margaret M. Williams, Stuart M. Sprague, S. Chow, Diego Brancaccio, Yumi Kubo, P. Dykes, E. de Francesco Daher, C. Erley, Joanna Matuszkiewicz-Rowińska, T. Minga, I. Dasgupta, Galen S. Wagner, N. Marchetta, R. Rigolosi, P. Raguram, P. Lang, P. Cambier-Dwelschauwers, A. Tsang, M. Schonefeld, W. Bentkowski, Z. Sharon, Daniel Batlle, James T. McCarthy, M. Vital Flores, M. Rambausek, A. Zemtchenkov, Fabio Malberti, V. Thakur, O. Domashenko, D. Wheeler, J. Capelli, Bernard Jones, D. Uehlinger, K. Olgaard, K. Lhotta, M. Bernardo, S. Goldberger, Alison Thomas, E. Dunnigan, A. Ksiazek, A. Assefi, C. Poole, G. Rosa Diez, G. Newman, J. Cotton, C. Combe, B. Murthyr, Sharon M. Moe, H. Neumayer, J. Mittleman, Robert G. Fassett, W. Cleveland, F. van der Sande, C. Vela, H. Fessi, J. Robertson, Giuseppe Cannella, Bryan N. Becker, João M. Frazão, V. Shilo, M. Rano, J. De Meester, R. Fiedler, J. Floege, B. Murray, Giovambattista Capasso, F. Dellanna, J. Luiz Gross, K. Tucker, C. Santiago, Paul J. Martin, M. Nowicki, L. Friedman, William G. Goodman, G. Diez, Markus Ketteler, S. Arfeen, I. Mezei, J. Ortiz, Elizabeth E. Brown, Deborah Zimmerman, Aleix Cases, M. El Khatib, Martine Leblanc, R. Daelemans, K. Malireddi, C. Rikker, R. Gladish, F. Aranda Verástegui, R. Kopelman, B. Borbas, J. Buerkert, K. Ntoso, J. Peña, V. Garcia, C. West, M. Azer, J. Kwan, J. Sterrett, P. Swift, A. Raff, R. Kohli, S. Lew, Steven J. Rosansky, H. Graf, K. Bouman, F. Skinner, C. Tielemans, S. Ferreira Filho, Jocemir Ronaldo Lugon, M. Weinberg, Parfrey, P. S., Drueke, T. B., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Kubo, Y., Dehmel, B., Goodman, W. G., Chertow, G. M., Santos, J., Najun Zarazaga, C., Marin, I., Garrote, N., Cusumano, A., Penalba, N., Del Valle, E., Juncos, L., Martinez Saye, J., Lef, L., Altobelli, V., Petraglia, G., Rosa Diez, G., Douthat, W., Lobo, J., Gallart, C., Lafalla, A., Diez, G., Linares, B., Lopez, N., Ramirez, N., Gonzalez, R., Valtuille, R., Beresan, H., Hermida, O., Rudolf, G., Marchetta, N., Rano, M., Ramirez, M., Garcia, N., Gillies, A., Jones, B., Pedagogos, E., Walker, R., Talaulikar, G., Bannister, K., Suranyi, M., Kark, A., Roger, S., Kerr, P., Disney, A., Mount, P., Fraenkel, M., Mathew, M., Fassett, R., Jose, M., Hawley, C., Lonergan, M., Mackie, J., Ferrari, P., Menahem, S., Sabto, J., Hutchison, B., Langham, R., Pollock, C., Holzer, H., Oberbauer, R., Arias, I., Graf, H., Mayer, G., Lhotta, K., Neyer, U., Klauser, R., Hoerl, W., Horn, S., Kovarik, J., Kramar, R., Eigner, M., Dhaene, M., Billiouw, J., De Meester, J., Warling, X., Cambier-Dwelschauwers, P., Evenepoel, P., Daelemans, R., Dratwa, M., Maes, B., Stolear, J., Dejagere, T., Vanwalleghem, J., Bouman, K., Jadoul, M., Peeters, J., Vanholder, R., Tielemans, C., Donck, J., Almeida, F., Picollo de Oliveira, J., Burdmann, E., Garcia, V., Saldanha Thome, F., Deboni, L., Bregman, R., Lugon, J., Araujo, S., Ferreira Filho, S., de Francesco Daher, E., Sperto Baptista, M., Carvalho, A., D'Avila, D., Moyses Neto, M., Yu, L., Bastos, M., Sampaio Lacativa, P., Jorgetti, V., de Almeida Romao, E., Cardeal da Costa, J., Pecoits Filho, R., Gordan, P., Salgado, N., Teixeira Araujo, M., Neiva Coelho, S., Oliveira, I., Moyses, R., Vasconcellos, L., Batista, P., Luiz Gross, J., Pedrosa, A., Cournoyer, S., Leblanc, M., Chow, S., Karunakaran, S., Wong, G., Tobe, S., Desmeules, S., Zimmerman, D., Murphy, S., Montambault, P., Donnelly, S., Macrae, J., Culleton, B., Soroka, S., Rabbat, C., Jindal, K., Vasilevsky, M., Michaud, M., Wijeyesinghe, E., Zacharias, J., Lok, C., Muirhead, N., Verrelli, M., Da Roza, G., Sapir, D., Olgaard, K., Daugaard, H., Brandi, L., Jensen, P., Boulechfar, H., Ang, K., Simon, P., Rieu, P., Brunet, P., Touchard, G., London, G., Urena Torres, P., Combe, C., Durrbach, A., Ortiz, J., Hannedouche, T., Vela, C., Lionet, A., Ryckelynck, P., Zaoui, P., Choukroun, G., Fessi, H., Lang, P., Stroumza, P., Joly, D., Mousson, C., Laville, M., Dellanna, F., Erley, C., Braun, J., Rambausek, M., Riegel, W., Klingberg, M., Schwertfeger, E., Wizemann, V., Eckardt, K., Reichel, H., Passauer, J., Hubel, E., Frischmuth, N., Liebl, R., Fiedler, R., Schwenger, V., Vosskuhler, A., Kunzendorf, U., Renders, L., Rattensberger, D., Rump, L., Ketteler, M., Neumayer, H., Zantvoort, F., Stahl, R., Ladanyi, E., Kulcsar, I., Mezei, I., Csiky, B., Rikker, C., Arkossy, O., Berta, K., Szegedi, J., Major, L., Ferenczi, S., Fekete, A., Szabo, T., Zakar, G., Wagner, G., Kazup Erdelyine, S., Borbas, B., Eustace, J., Reddan, D., Capasso, G., Locatelli, F., Villa, G., Cozzolino, M., Brancaccio, D., Messa, P., Bolasco, P., Ricciardi, B., Malberti, F., Moriero, E., Cannella, G., Ortalda, V., Stefoni, S., Frasca, G., Cappelli, G., Albertazzi, A., Zoccali, C., Farina, M., Elli, A., Avella, F., Ondei, P., Mingardi, G., Errico, R., Losito, A., Di Giulio, S., Pertosa, G., Schena, F., Grandaliano, G., Gesualdo, L., Auricchio, M., Bochicchio-Ricardelli, T., Aranda Verastegui, F., Pena, J., Chew Wong, A., Cruz-Valdez, J., Torres Zamora, M., Solis, M., Sebastian Diaz, M., Vital Flores, M., Alvarez Sandoval, E., van den Dorpel, M., Brink, H., Van Kuijk, W., Vermeij, C., Smak Gregoor, P., Hagen, E., van der Sande, F., Klinger, M., Nowicki, M., Muszytowski, M., Bidas, K., Bentkowski, W., Wiecek, A., Ksiazek, A., Marczewski, K., Ostrowski, M., Switalski, M., Sulowicz, W., Matuszkiewicz-Rowinska, J., Mysliwiec, M., Durlik, M., Rutkowski, B., Macario, F., Carvalho, B., Frazao, J., Machado, D., Weigert, A., Andrusev, A., Khrustalev, O., Zemtchenkov, A., Gurevich, K., Staroselsky, K., Khadikova, N., Rozhinskaya, L., Timokhovskaya, G., Strokov, A., Balkarova, O., Ermolenko, V., Kolmakova, E., Komandenko, M., Timofeev, M., Shilo, V., Shostka, G., Smirnov, A., Anashkin, V., Volgina, G., Domashenko, O., Gurevich, A., Perlin, D., Martinez Garcia, J., Andres Ribes, E., Coll Piera, E., Fernandez Lucas, M., Galicia, M., Prados, M., Gonzalez, M., Romero, R., Martin de Francisco, A., Montenegro, J., Santiago, C., Garcia, F., Alcazar de La Ossa, J., Arrieta, J., Pons, J., Martin-Malo, A., Soler Amigo, J., Cases, A., Sterner, G., Jensen, G., Wikstrom, B., Jacobson, S., Lund, U., Weiss, L., Stahl, A., von Albertini, B., Burnier, M., Meier, P., Martin, P., Uehlinger, D., Dickenmann, M., Yaqoob, M., Zehnder, D., Kalra, P., Padmanabhan, N., Roe, S., Eadington, D., Pritchard, N., Hutchison, A., Davies, S., Wilkie, M., Davies, M., Pai, P., Swift, P., Kwan, J., Goldsmith, D., Tomson, C., Stratton, J., Dasgupta, I., Sarkar, S., Moustafa, M., Gandhi, K., Jamal, A., Galindo-Ramos, E., Tuazon, J., Batlle, D., Tucker, K., Schiller-Moran, B., Assefi, A., Martinez, C., Samuels, L., Goldman, J., Cangiano-Rivera, J., Darwish, R., Lee, M., Topf, J., Kapatkin, K., Baer, H., Kopelman, R., Acharya, M., Tharpe, D., Bernardo, M., Nader, P., Guzman-Rivera, J., Pergola, P., Sekkarie, M., Alas, E., Zager, P., Liss, K., Navarro, J., Roppolo, M., Denu-Ciocca, C., Kshirsagar, A., El Khatib, M., Kant, K., Scott, D., Murthyr, B., Finkelstein, F., Keightley, G., Mccrary, R., Pitone, J., Cavalieri, T., Tsang, A., Pellegrino, B., Schmidt, R., Ahmad, S., Brown, C., Friedman, E., Mittman, N., Fadem, S., Shapiro, W., Reddy, M., Goldberger, S., Woredekal, Y., Agarwal, A., Anger, M., Haque, M., Chidester, P., Kohli, R., Rubinstein, S., Newman, G., Gladish, R., Ayodeji, O., Soman, S., Sprague, S., Hunt, N., Gehr, T., Rizk, D., Warnock, D., Polack, D., Pahl, M., Fischer, D., Dreyer, P., James, G., Husserl, F., Rogers, T., Raff, A., Sedor, J., Silver, M., Smith, M., Steinberg, S., Delgiorno, T., Jones, E., Cunha, P. D., Cheng, J., Pogue, V., Blumenthal, S., Brown, E., Charytan, C., Buerkert, J., Cook, M., Felsenfeld, A., Tareen, N., Gupta, A., Herman, T., Diamond, S., Hura, C., Laski, M., Maclaurin, J., Plumb, T., Brosnahan, G., Kumar, J., Henriquez, M., Poole, C., Osanloo, E., Matalon, A., Sholer, C., Arfeen, S., Azer, M., Belledonne, M., Gross, M., Dunnigan, E., Mcconnell, K., Becker, B., Skinner, F., Rigolosi, R., Spiegel, D., Stegman, M., Patak, R., Streja, D., Ranjit, U., Youell, T., Wooldridge, T., Stafford, C., Cottiero, R., Weinberg, M., Schonefeld, M., Shahmir, E., Hazzan, A., Ashfaq, A., Bhandari, K., Cleveland, W., Culpepper, M., Golden, J., Lai, L., Lien, Y., Lorica, V., Robertson, J., Malireddi, K., Morse, S., Thakur, V., Israelit, A., Raguram, P., Alfred, H., Weise, W., Al-Saghir, F., El Shahawy, M., Rastogi, A., Nissenson, A., Kopyt, N., Lynn, R., Lea, J., Mcclellan, W., Teredesai, P., Ong, S., Tolkan, S., Sugihara, J., Minga, T., Mehrotra, R., Minasian, R., Bhatia, D., Specter, R., Capelli, J., Sidhu, P., Dalal, S., Dykes, P., Khan, M., Rahim, F., Saklayen, M., Thomas, A., Michael, B., Torres, M., Al-Bander, H., Murray, B., Abukurah, A., Gupta, B., Nosrati, S., Raja, R., Zeig, S., Braun, M., Amatya, A., Endsley, J., Sharon, Z., Dolson, G., Dumler, F., Ntoso, K., Rosansky, S., Kumar, N., Gura, V., Thompson, N., Goldfarb, D., Halligan, R., Middleton, J., Widerhorn, A., Arbeit, L., Arruda, J., Crouch, T., Friedman, L., Khokhar, S., Mittleman, J., Light, P., Taparia, B., West, C., Cotton, J., Dhingra, R., Kleinman, L., Arif, F., Lew, S., Nammour, T., Sterrett, J., Williams, M., Ramirez, J., Rubin, J., Mccarthy, J., Noble, S., Chaffin, M., and Rekhi, A.
- Subjects
Parathyroidectomy ,Adult ,Male ,medicine.medical_specialty ,Cinacalcet ,Epidemiology ,medicine.medical_treatment ,Calcimimetic Agents ,Critical Care and Intensive Care Medicine ,Lower risk ,Severity of Illness Index ,CKD ,cardiovascular disease ,hemodialysis ,hyperparathyroidism ,mineral metabolism ,Age Factors ,Aged ,Aged, 80 and over ,Cardiovascular Diseases ,Cinacalcet Hydrochloride ,Female ,Humans ,Hyperparathyroidism, Secondary ,Kidney Failure, Chronic ,Kidney Transplantation ,Middle Aged ,Renal Dialysis ,Nephrology ,Transplantation ,Internal medicine ,medicine ,Intensive care medicine ,Hyperparathyroidism ,business.industry ,Original Articles ,medicine.disease ,Secondary hyperparathyroidism ,Hemodialysis ,business ,medicine.drug - Abstract
Background andobjectivesThecalcimimeticcinacalcet reduced therisk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older ($65 years, n=1005) and younger (,65 years, n=2878) patients. Design, setting, participants, & measurements Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) was a global, multicenter, randomized placebo-controlled trial in 3883 prevalent patients on hemodialysis, whose outcomes included death, major CV events, and development of severe unremitting HPT. The age subgroup analysis was prespecified. ResultsOlderpatients hadhigher baselineprevalenceof diabetesmellitusandCV comorbidity. Annualizedrates of kidney transplantation and parathyroidectomy were .3-fold higher in younger relative to older patients and were more frequent in patients randomized to placebo. In older patients, the adjusted relative hazard (95% confidence interval) for the primary composite (CV) end point (cinacalcet versus placebo) was 0.70 (0.60 to 0.81); in younger patients, the relative hazard was 0.97 (0.86 to 1.09). Corresponding adjusted relative hazards for mortality were 0.68 (0.51 to 0.81) and 0.99 (0.86 to 1.13). Reduction in the risk of severe unremitting HPT was similar in both groups. Conclusions In the EVOLVE trial, cinacalcet decreased the risk of death and of major CV events in older, but not younger, patients with moderate to severe HPT who were receiving hemodialysis. Effect modification by age may be partly explained by differences in underlying CV risk and differential application of cointerventions that reduce parathyroid hormone. Clin J Am Soc Nephrol 10: ccc–ccc, 2015. doi: 10.2215/CJN.07730814
- Published
- 2015
12. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study
- Author
-
R, Provenzano, A, Besarab, I C, Macdougall, D H, Ellison, A P, Maxwell, W, Sulowicz, M, Klinger, B, Rutkowski, R, Correa-Rotter, and F C, Dougherty
- Subjects
Adult ,Aged, 80 and over ,Male ,Analysis of Variance ,Time Factors ,Dose-Response Relationship, Drug ,Anemia ,Middle Aged ,Recombinant Proteins ,Polyethylene Glycols ,Hemoglobins ,Treatment Outcome ,Renal Dialysis ,Area Under Curve ,Ferritins ,Humans ,Kidney Failure, Chronic ,Regression Analysis ,Erythropoiesis ,Female ,Erythropoietin ,Biomarkers ,Aged ,Follow-Up Studies - Abstract
This study was designed to assess the potential of the continuous erythropoietin receptor activator (C.E.R.A.) to correct anemia at extended administration intervals in erythropoiesis-stimulating agent-naīve patients with chronic kidney disease (CKD) not on dialysis and to determine its optimal starting dose.Patients were assigned to subcutaneous C.E.R.A. at 3 doses: 0.15, 0.30 and 0.60 microg/kg/wk. During the first 6 weeks, dose adjustments for efficacy were not permitted in order to assess dose response. Within each of the 3 dose groups, patients were randomized to receive C.E.R.A. QW, Q2W or Q3W; the total dose during the first 6 weeks was the same for a particular dose group across the frequency subgroups. During the next 12 weeks, dose was adjusted according to predefined hemoglobin (Hb) criteria. The primary efficacy parameter was change in Hb over 6 weeks, estimated from regression analysis between baseline and the point at which the patient received a dose change or blood transfusion. It therefore provided an estimate of Hb increase based on starting dose. Other endpoints included Hb response rate (proportion of patients with a Hb increase1.0 g/dl on 2 consecutive occasions). A 1-year extension period investigated long term tolerability and efficacy.A dose-dependent relationship was noted in the mean change in Hb from baseline over 6 weeks (p0.0001), independent of administration schedule (p = 0.9201). There was also a significant relationship between Hb change and median serum C.E.R.A. concentration (p0.0001). Erythropoietic responses were sustained in all groups with mean changes from baseline in Hb1.2 g/dl observed at dosesor = 0.30 microg/kg/wk. Hb response rate increased with increasing dose: 67, 72 and 90% with C.E.R.A. 0.15, 0.30 and 0.60 microg/kg/wk, respectively. Generally, the median Hb response time was faster with increasing dose (89, 43 and 31 days, respectively). Response was unrelated to administration frequency. Stable Hb concentrations were maintained throughout the 1-year extension period. C.E.R.A. was generally well tolerated, and the most common adverse events were hypertension, urinary tract infection and renal failure.C.E.R.A. corrected anemia and maintained sustained and stable control of Hb over 1 year. These results suggest that 0.60 microg/kg subcutaneous C.E.R.A. given twice monthly is a suitable starting dose for further investigation in Phase III studies in patients with CKD not on dialysis.
- Published
- 2007
13. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction
- Author
-
Robert D. Colucci, Christopher Banfield, W. Sulowicz, Sudhakar Pai, M.B. Affrime, Paul Glue, and Chin-Chung Lin
- Subjects
Adult ,Male ,medicine.medical_specialty ,Phenylcarbamates ,Cmax ,Urology ,Renal function ,Urine ,urologic and male genital diseases ,Felbamate ,Pharmacokinetics ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Pharmacology ,Volume of distribution ,business.industry ,Original Articles ,Middle Aged ,medicine.disease ,Endocrinology ,Propylene Glycols ,Toxicity ,Kidney Failure, Chronic ,Anticonvulsants ,business ,medicine.drug ,Kidney disease - Abstract
Aims The purpose of this study was to evaluate the effects of renal impairment on the single-dose pharmacokinetics of the antiepileptic felbamate. Methods Twelve subjects with three levels of renal dysfunction (creatinine clearance >30–80, >10–30 or 5–10 m min−1 ) and four controls with normal renal function (creatinine clearance >80 ml min−1 were studied). Plasma and urine samples were obtained for 144 h following administration of a single 1200 mg dose. Results Compared with controls, apparent total body clearance, renal clearance and urinary excretion of felbamate were decreased, and half-life, Cmax and AUC values were increased in subjects with renal dysfunction. The magnitude of these changes was associated with the degree of renal dysfunction. Nonrenal clearance and apparent volume of distribution values were also lower in renal dysfunction subjects, but there was no association between the extent of these changes and degree of renal dysfunction. Renal clearance of felbamate accounted for approximately 30% of apparent total body clearance in the control group and from 9–22% in the renal failure patients. Renal clearance of felbamate was significantly correlated with creatinine clearance (r2=0.75; P
- Published
- 1997
- Full Text
- View/download PDF
14. [History, present status and perspectives of the development of renal replacement therapy in South-Eastern of Poland]
- Author
-
W, Sulowicz, M, Krzanowki, and B, Walatek
- Subjects
Renal Replacement Therapy ,Prevalence ,Humans ,Kidney Failure, Chronic ,Poland - Published
- 2002
15. PO17-495 VALUE OF DOPPLER ULTRASONOGRAPHY IN RENAL ARTERY STENOSIS RECOGNITION
- Author
-
W. Sulowicz, T. Stompor, Wiesława Tracz, Grzegorz Kopeć, D. Rzeznik, Tadeusz Przewłocki, A. Kozanecki, Piotr Pieniazek, and A. Kablak-Ziembicka
- Subjects
medicine.medical_specialty ,business.industry ,General Medicine ,Renal artery stenosis ,medicine.disease ,symbols.namesake ,Internal Medicine ,medicine ,symbols ,Radiology ,Ultrasonography ,Cardiology and Cardiovascular Medicine ,business ,Value (mathematics) ,Doppler effect - Published
- 2007
- Full Text
- View/download PDF
16. Diabetes - Clinical studies
- Author
-
S. Molsted, A. P. Harrison, I. Eidemak, J. L. Andersen, D. Kohan, B. Coll, S. Wen, M. Molitch, Y. Pritchett, P. Audhya, T. Garimella, J. Brennan, D. Andress, M. Hecking, M. Haidinger, J. Werzowa, D. Doller, W. H. Horl, G. Pacini, F. K. Port, M. D. Saemann, O. Loboda, I. Dudar, V. Krot, M. Velichko, H. Haller, S. Ito, J. Izzo, A. Januszewicz, J. Menne, A. Mimran, T. J. Rabelink, E. Ritz, L. M. Ruilope, L. C. Rump, G. Viberti, J. J. Crespo, M. Dominguez-Sardina, M. T. Rios, A. Moya, S. M. Gomara, L. Meijide, A. Mojon, D. E. Ayala, R. C. Hermida, null Investigadores Proyecto Hygia, E. Sineiro, M. C. Castineira, M. J. Fontao, S. Lorenzo, K. Tanaka, S. Hara, A. Kushiyama, Y. Yoshida, Y. Ubara, S. Mizuiri, A. Aikawa, S. Kawazu, I. Topchii, P. Semenovykh, V. Galchinskaya, V. Denisenko, T. Scherban, P. Budhiraja, M. Popovtzer, J. Nieto, P. Giralt, M. J. Ballesteros, C. Mora, A. Carreno, G. Gutierrez, E. Sabath, P. Garcia-Solis, J. C. Solis-Saenz, H. Hernandez-Montiel, I. N. Perez-Maldonado, M. L. Robles-Osorio, P. Ravani, P. Pecchini, R. Quinn, F. Mallamaci, G. Tripepi, F. Malberti, M. Mieth, R. Mass, C. Zoccali, G. Faustmann, K. Ottl, S. Fuchs, H. Sourij, H. Hafner-Giessauf, W. Ribitsch, J. Greilberger, G. Khoschsorur, A. Meinitzer, B. Tiran, B. M. Winklhofer-Roob, J. M. Roob, J. Al Wakeel, D. Hammad, A. Mitwalli, A. Al Harbi, A. Al Suwaida, M. Al Ghonaim, K. Kaul, A. Hodgkinson, J. Tarr, A. Shore, K. Gooding, M. Gilchrist, A. Millward, E. Kohner, R. Chibber, A. P. Silva, A. Cabrita, A. T. Pinho, I. Maia, A. Guedes, M. Faisca, P. L. Neves, N. Prasad, S. Barai, S. Gambhir, R. K. Sharma, A. Gupta, O. El-Minshawy, E. El-Bassuoni, V. Driyanskaya, V. Alekseeva, A. Montanari, L. Musiari, G. Pela, I. Pelloni, F. Fellini, A. Cabassi, A. Biggi, M. Kolesnyk, L. Korol, G. Nikulina, L. Migal, L. Petrica, M. Petrica, A. Vlad, D. C. Jianu, G. Gluhovschi, C. Ianculescu, C. Firescu, V. Dumitrascu, F. Gadalean, S. Giju, C. Gluhovschi, F. Bob, S. Ursoniu, S. Velciov, G. Bozdog, O. Milas, R. Marian, M. Peckova, M. Horackova, O. Schuck, V. Zamrazil, M. Hill, P. Svab, J. Jerry, J. Charvat, A. Lacquaniti, B. Pintaudi, V. Donato, A. Di Benedetto, V. Chirico, G. Di Vieste, M. Buemi, N. Efimova, E. Borisova, K. Ishioka, M. Iwagami, R. Furuya, Y. Mochida, M. Oka, K. Maesato, M. Takahashi, R. Komi, H. Moriya, T. Ohtake, S. Hidaka, S. Kobayashi, H. C. Park, S. J. Moon, J. E. Lee, J. S. Park, S. K. Ha, P. Miarka, M. Walus-Miarka, M. Dubiel, M. Stompor, B. Tabor-Ciepiela, T. Grodzicki, B. Idzior-Walus, W. Sulowicz, T. Kawaguchi, Y. Otsuka, A. Takeda, Y. Ogiyama, Y. Yamauchi, M. Murata, T. Suzuki, K. Horike, D. Inaguma, K. Morozumi, T. Basturk, M. Akcay, R. Albayrak, and A. Unsal
- Subjects
Transplantation ,Nephrology - Published
- 2011
- Full Text
- View/download PDF
17. Protein-energy wasting, inflammation and oxidative stress in CKD 5D
- Author
-
L. Rosales, O. Vega, L. Usvyat, S. Thijssen, N. Levin, P. Kotanko, T. Miyamoto, A. Witasp, A. Rashid Qureshi, O. Heimburger, P. Barany, L. Nordfors, B. Lindholm, P. Stenvinkel, J. Jesus Carrero, M. Kalousova, H. Benakova, A. A. Kubena, S. Dusilova-Sulkova, V. Tesar, T. Zima, Y. J. Lee, M. S. Kim, B. G. Song, S. Cho, S. R. Kim, M. Stockler-Pinto, J. Lobo, C. Moraes, A. Barros, N. Farage, G. Boaventura, D. Mafra, O. Malm, S. Matsuda, N. Akaike, K. Kajiwara, D. Tovbin, S. Kesari, D. Sola-Del Valle, J. Barasch, A. Douvdevani, M. Zlotnik, A. Abd Elkadir, S. Storch, M. Sarikaya, F. Sari, J. Gunes, M. Eren, R. Cetinkaya, J.-C. Hwang, T.-L. Ma, C.-T. Wang, H. Ogawa, T. Nagaya, Y. Ota, M. Sarai, O. Oda, B. Biavo, C. Uezima, M. E. Costa, C. Barros, J. P. Martins, E. Ribeiro Jr, C. Tzanno-Martins, H. Honda, N. Kimata, K. Wakai, T. Akizawa, J. Droulias, V. Filliponi, C. Argyropoulos, R. Fischer, C. Papakonstantinou, C. Papadopoulos, A. Kouvelis, G. Zervas, E. Dampolia, N. Zerefos, D. Valis, C. Sarcina, I. Baragetti, P. Uboldi, L. Buzzi, K. Garlaschelli, F. Ferrario, V. Terraneo, G. D. Norata, A. L. Catapano, C. Pozzi, G. Conti, D. Santoro, D. Caccamo, S. Condello, D. Pazzano, V. Savica, R. Jentile, C. Fede, G. Bellinghieri, R. Zortcheva, V. Ikonomov, B. Galunska, D. Paskalev, D. Dobreva, D. Ivanova, M. Tsunoda, R. Ikee, N. Sasaki, N. Sato, N. Hashimoto, L. Korol, I. Dudar, L. Migal, Y. Gonchar, I. Seleznova, V. Ischenko, M. Erkmen Uyar, E. Tutal, Z. Bal, N. Ahmed, S. Sezer, D. Fedak, M. Kuzniewski, D. Pawlica, B. Kusnierz-Cabala, B. Solnica, M. Drozdz, K. Janda, W. Sulowicz, J. Kopec, M. Banach, and V. Leal
- Subjects
Transplantation ,medicine.medical_specialty ,Endocrinology ,Nephrology ,business.industry ,Internal medicine ,medicine ,Inflammation ,Protein energy wasting ,medicine.symptom ,medicine.disease_cause ,business ,Oxidative stress - Published
- 2011
- Full Text
- View/download PDF
18. PRCA SUCCESSFULLY TREATED WITH IMMUNOSUPPRESSION FOLLOWED BY KIDNEY TRANSPLANTATION
- Author
-
K. Galazka, P. Jaskowski, M. Krzanowski, W. Dzugan, K. Janda, K. Dziewanowski, W. Sulowicz, A. Krasniak, E. Chowaniec, and I. Kaczmarczyk
- Subjects
Nephrology ,Transplantation ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine.medical_treatment ,medicine ,Urology ,Immunosuppression ,medicine.disease ,business ,Kidney transplantation - Published
- 2010
- Full Text
- View/download PDF
19. Diabetes mellitus - clinical studies - 2
- Author
-
A. Sattar, István Wittmann, Domenico Corradi, M. Haapio, Bernhard M.W. Schmidt, Susumu Ogawa, Ruth Mitchell, Carlos Alberto Mayora Aita, Colin J. Meyer, Peter-Rene Mertens, Esztella Mikolás, P. Miarka, Tatjana Cvetkovic, Ling Li, Georgios Hadjigeorgiou, J.A. Kellum, JoséMauro Vieira, Pál Brasnyó, Vuddhidej Ophascharoensuk, Hiroshi Sato, Eszter Fehér, Mártóon Mohás, Julia B. Lewis, Yusuke Osaki, Ulrike Raff, Tuneo Ishizuka, Mirela Liana Gliga, Sadayoshi Ito, Maximilian von Eynatten, Augusto Vaglio, Spyridon Arampatzis, Ramesh Chandra Vyasam, F. Nurhan Ozdemir, Jutalai Tanterdtham, M. Walus-Miarka, Marcus Baumann, Laura Pavone, Ausilia Maione, Carlos Kornhauser, Weiqian Sun, Renate Koppensteiner, Myrto Giannopoulou, Grigore Aloiziu Dogaru, Nestor Schor, August Heidland, Srilatha Vadlamudi, C. Argyropoulos, Peter Boor, Somkiat Vasuvattakul, L. Weissfeld, Alessandra Palmisano, Gloria Barbosa-Sabaner, M. Stompor, Jae Sung Lee, Demet Yavuz, Vladimir Arandjelovic, Ioanna Chronopoulou, Paisal Parichatikanond, Maria Goretti Polito, Takashi Nakamichi, Masanori Ito, Denise H.M.P. Diniz, Katarína Šebeková, T. Grodzicki, Bi-Cheng Liu, Toshio Mochizuki, Federico Alberici, Roberto Zatz, Jamille Godoy Mendes, Pingyan Shen, M. de Cal, Qi Long, Tadayuki Okumoto, M. Unruh, Nan Chen, Kraiwiporn Kiattisunthorn, Predrag Vlahovic, Gerit-Holger Schernthaner, Carlo Salvarani, Ilma Modanez, Per M. Humpert, Stacey Ruiz, Peggy Gao, Boonyarit Cheunsuchon, M. Batur Canoz, Lei Yan, Guntram Schernthaner, Dietmar Zdunek, Maria Dardioti, Claudio Ronco, Simeone Andrulli, Silvia M. Titan, Hans-Henrik Parving, Mohammed Bashir, Roland E. Schmieder, Florian Hoellerl, Hideyuki Inoue, Kristína Klenovicsová, Daniel Cruz, W. Sulowicz, Norman K. Hollenberg, Antonio Nicolucci, Ioannis Stefanidis, Donal O'Shea, Paulo C. Fortes, Vladislav Stefanovic, Seiji Hashimoto, Edmund J. Lewis, Ines Casazza, F. Nalesso, Wattana B. Watanapa, Rosario Foti, Sasa Milenkovic, Sherwyn Schwartz, Gianna Mastroianni-Kirsztajn, Takayuki Yamada, Judit Cseh, Athakorn Kirakul, M. Krzanowski, Johannes Mann, Efthymios Dardiotis, Jeffrey G. Supko, T J Cawood, Angelika Bierhaus, Chiara Grasselli, Cornelia Zumpe, E. Chowaniec, Wen Zhang, Hyeong Cheon Park, Takuma Hosoya, Mihai Gliga, Frederik Persson, Pablo Pergola, Erika Oliveira da Silva, Jicheng Lv, Chien-Te Lee, Tasuku Nagasawa, Noemi Gutierrez-Romero, Alberto Pesci, Karsten Kreuer, Sung Jin Moon, Douglas Denham, Roberto Pecoits-Filho, Hong Zhang, Kriengsak Vareesangthip, B. Ciepiela, Miguel C. Riella, A.A. House, Ke-Dan Cai, Terry Ting-Yu Chiou, Silvia Regina Moreira, Ravi Raju Tatapudi, Craig A. Hurwitz, Davide Martorana, Peter P. Nawroth, Giovanni F.M. Strippoli, István András Szijártó, Jung Eun Lee, Inés Birlouez-Aragon, Takao Koike, Hong Ren, kos Mérei, Ampica Mangklabruk, Gabriella Moroni, Hai-yan Wang, Veronika Somoza, Thomas K. Schwarz, Johanna Brix, Branka Mitic, Zi-Lin Sun, Saori Nishio, Sufang Shi, Sung Kyu Ha, Xiaoxia Pan, Ravi Shankar Subramaniam, Georg Hess, P. Lentini, Prasad Gullipalli, Siren Sezer, Sankar D. Navaneethan, Soung Rok Sim, Marcel Roos, Rui Toledo Barros, Uwe Heemann, Jennifer Brady, Kazuhiro Nako, Markus P. Schneider, Barbara Murray, Tibor Vas, M. Dubiel, Giselle Saavedra, Carlo Buzio, Vidojko Djordjevic, Rue-Tsuan Liu, Daisuke Ito, Vassilios Liakopoulos, T. Stompor, Suchai Sritippayawan, Carmen Caldararu, and Takefumi Mori
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,Internal medicine ,Diabetes mellitus ,medicine ,business ,medicine.disease - Published
- 2009
- Full Text
- View/download PDF
20. Beta-glucuronidase activity in neutrophils of patients with malignancies
- Author
-
J, Lisiewicz, P, Moszczyński, and W, Sulowicz
- Subjects
Male ,Neutrophils ,Neoplasms ,Humans ,Female ,Glucuronidase - Abstract
The human neutrophils induce cytotoxic effects on mammalian tumor cells. Hence it may be expected that intracellular enzymatic deficiencies of neutrophils may represent another cancer risk factor. In 205 patients with various malignancies the neutrophil beta-glucuronidase activity has been determined using a semiquantitative cytochemical method. A statistically significant deficiency of this enzyme in neutrophils has been observed in patients with precancerous states of the larynx, cancer of the larynx after radiotherapy and patients with cancer of large intestine. Patients with cancer of the lung and cancer of the stomach showed no changes with that regard whereas those with cancer of the breast demonstrated an increased enzyme activity.
- Published
- 1990
21. SMOKING AND RENAL FAILURE IN POLYCYSTIC KIDNEY DISEASE (ADPKD)
- Author
-
T, Schiavello, primary, V, Burke, additional, P, Jasik, additional, S, Melsom, additional, W, Sulowicz, additional, A, Krasniak, additional, T, Stompor, additional, L, Kalaydjieva, additional, M, Thomas, additional, and W, Lim, additional
- Published
- 2002
- Full Text
- View/download PDF
22. Second Nephrology Summer School
- Author
-
W. Sulowicz and Eberhard Ritz
- Subjects
Nephrology ,Transplantation ,medicine.medical_specialty ,Medical education ,business.industry ,Internal medicine ,medicine ,business - Published
- 1999
- Full Text
- View/download PDF
23. Special announcements. Nephrology Summer School, July 16-18th, 1999, Cracow, Poland
- Author
-
W Sulowicz
- Subjects
Nephrology ,Transplantation ,medicine.medical_specialty ,business.industry ,Internal medicine ,Family medicine ,Medicine ,Optometry ,business - Published
- 1999
- Full Text
- View/download PDF
24. The effect of renal function on felbamate clearance
- Author
-
Chin-Chung Lin, Pascale Reidenberg, W. Sulowicz, Jeffrey W. Meehan, D.P. Glue, Robert D. Colucci, M.B. Affrime, Christopher Banfield, and Sudhakar Pai
- Subjects
Pharmacology ,medicine.medical_specialty ,business.industry ,medicine ,Urology ,Renal function ,Pharmacology (medical) ,Effective renal plasma flow ,PAH clearance ,business ,Felbamate ,medicine.drug - Published
- 1996
- Full Text
- View/download PDF
25. Immunological parameters in patients with gastric cancer at different clinical stages
- Author
-
P, Moszczynski and W, Sulowicz
- Subjects
Adult ,Male ,Stomach Neoplasms ,Humans ,Immunoglobulins ,Female ,Lymphocytes ,Middle Aged ,Aged ,Skin Tests - Abstract
Lymphocyte subpopulations, cutaneous reactivity to tuberculin and distreptase, and immunoglobulin level were investigated in 32 untreated patients with gastric cancer at different stages of advancement and in healthy controls. Statistically significant decrease in the number of T-lymphocytes, accompanied by a deficient cutaneous reactivity, as well as a decrease in the number of B-lymphocytes and lowered A, G, and M immunoglobulin concentration were found in patients with grade III cancer.
- Published
- 1985
26. Activity of some lysosomal enzymes in neutrophils from peripheral blood of patients with digestive tract cancer at different clinical stages of the disease. A cytochemical study
- Author
-
W, Sulowicz
- Subjects
Adult ,Male ,Neutrophils ,Acid Phosphatase ,Carcinoma ,Adenocarcinoma ,Middle Aged ,Stomach Neoplasms ,Acetylglucosaminidase ,Colonic Neoplasms ,Humans ,Female ,Lysosomes ,Aged ,Glucuronidase - Abstract
Activity of acid phosphatase, beta-glucuronidase and N-acetyl-beta-glucosaminidase was investigated cytochemically in neutrophils from peripheral blood of 22 untreated patients with gastric cancer, 8 patients with cancer of large intestine and in 40 healthy individuals. Differences in the activity of enzymes studied were demonstrated between patients at different clinical stages of cancer advancement, as well as between cancer patients and healthy subjects. Most significant changes were observed in patients with initial (1st stage) cancer, as compared with the control group, including decrease of acid phosphatase and beta-glucuronidase activity, accompanied by an enhanced N-acetyl-beta-glucosaminidase activity. The possible mechanism of these changes is discussed.
- Published
- 1981
27. [Spontaneous nitroblue tetrazolium reduction test and neutrophil alkaline phosphatase activity of the peripheral blood on pregnant and parturient women]
- Author
-
W, Sulowicz, W, Dawidiuk, M, Szczepaniec, H, Strzałka, and M, Jakubiec
- Subjects
Adult ,Enzyme Activation ,Neutrophils ,Pregnancy ,Nitroblue Tetrazolium ,Pregnancy Trimester, Third ,Postpartum Period ,Humans ,Tetrazolium Salts ,Female ,Alkaline Phosphatase ,Oxidation-Reduction - Published
- 1981
28. The neutrophil and lymphocyte nonspecific esterase in patients with malignancies
- Author
-
W, Sulowicz, J, Lisiewicz, T, Cichocki, and P, Moszczyński
- Subjects
Male ,Leukocyte Count ,Lung Neoplasms ,Neutrophils ,Stomach Neoplasms ,Colonic Neoplasms ,Humans ,Female ,Lymphocytes ,Neoplasm Metastasis ,Carboxylic Ester Hydrolases ,Carboxylesterase ,Neoplasm Proteins - Abstract
In 52 patients with malignancies such as lung cancer, carcinoma of the stomach, and cancer of the colon (25, 18, and 9 cases, respectively) activity and intracellular localization of alpha-naphthyl acetate esterase has been evaluated by means of semiquantitative cytochemical method. Patients with advanced metastatic process occurring during clinical evolution of those malignancies showed decreased activity of above enzyme within the peripheral blood neutrophils and decreased numbers of enzyme-positive lymphocytes having intact enzyme-positive lysosomal granules. The authors discuss the significance of that observation in relation to the enzymatic alterations of cells during antitumor response of immune system.
- Published
- 1984
29. [Atypical motphology of the esophagus in a patient with hiatal hernia]
- Author
-
J, Lankosz and W, Sulowicz
- Subjects
Hernia, Diaphragmatic ,Esophagus ,Hernia, Hiatal ,Humans ,Female ,Esophageal and Gastric Varices ,Gastrointestinal Hemorrhage ,Aged - Published
- 1976
30. Cytochemical study on the glycogen content in neutrophils from peripheral blood of patients with gastrointestinal cancer
- Author
-
W, Sulowicz
- Subjects
Neutrophils ,Stomach Neoplasms ,Colonic Neoplasms ,Humans ,Glycogen - Abstract
The neutrophil glycogen content, as revealed by cytochemical staining, was determined in 22 patients with gastric cancer, 8 patients with cancer of large intestine and 40 healthy subjects. A statistically significant increase of the glycogen content in neutrophils obtained from patients with initial cancer stages as compared with healthy individuals and patients with advanced tumors was observed. The possible mechanism of these changes is discussed.
- Published
- 1984
31. [Spontaneous nitroblue tetrazolium reduction test in women during the perinatal period]
- Author
-
W, Sulowicz, W, Dawidiuk, M, Szczepaniec, and M, Jakóbiec
- Subjects
Adult ,Labor, Obstetric ,Neutrophils ,Pregnancy ,Nitroblue Tetrazolium ,Humans ,Tetrazolium Salts ,Female ,Bacterial Infections - Published
- 1977
32. [The nitroblue tetrazolium (NBT) test in selected respiratory tract diseases. The NBT test in differential diagnosis of pneumonia and pulmonary thromboembolism]
- Author
-
M, Szczepaniec and W, Sulowicz
- Subjects
Adult ,Diagnosis, Differential ,Adolescent ,Nitroblue Tetrazolium ,Humans ,Tetrazolium Salts ,Pneumonia ,Middle Aged ,Pulmonary Embolism ,Aged - Published
- 1976
33. Random migration of leukocytes and phagocytic activity of neutrophils in patients with cancer of gastrointestinal tract at different clinical stages
- Author
-
W, Sulowicz
- Subjects
Adult ,Inflammation ,Male ,Neutrophils ,Carcinoma ,Adenocarcinoma ,Middle Aged ,Chemotaxis, Leukocyte ,Phagocytosis ,Stomach Neoplasms ,Colonic Neoplasms ,Humans ,Female ,Aged - Abstract
Capillary leukocyte migration test and neutrophil phagocytosis test with Bacto-Latex were performed in 22 patients with gastric cancer, 8 patients with cancer of large intestine and 40 healthy subjects. Patients were divided into 3 groups on the basis of the clinical stage of the disease. Patients with initial (1st stage) cancer showed a statistically significant decrease of spontaneous leukocyte migration accompanied by increased neutrophil phagocytic activity, as compared with the control group (P less than 0.05). The mechanism of the observed changes is discussed.
- Published
- 1983
34. Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment.
- Author
-
Agersnap MA, Sonne K, Knudsen KM, and Sulowicz W
- Published
- 2023
- Full Text
- View/download PDF
35. Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment.
- Author
-
Agersnap MA, Sonne K, Knudsen KM, and Sulowicz W
- Subjects
- Humans, Kidney, Renal Dialysis, Area Under Curve, Renal Insufficiency, Kidney Failure, Chronic drug therapy
- Abstract
Background: Glepaglutide is a novel, ready-to-use, long-acting, glucagon-like peptide-2 (GLP-2) analog intended for the treatment of patients with short bowel syndrome (SBS). This study investigated the impact of renal function on the pharmacokinetics and safety of glepaglutide., Methods: In this 3-site, non-randomized, open-label study, 16 subjects were enrolled: 4 with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m
2 ), 4 with end stage renal disease (ESRD) not on dialysis (eGFR < 15 mL/min/1.73 m2 ), and 8 matching controls with normal renal function (eGFR ≥ 90 mL/min/1.73 m2 ). Blood samples were collected over a 14-day period following a single subcutaneous (SC) dose of glepaglutide 10 mg. Safety and tolerability were assessed throughout the study. The primary pharmacokinetic parameters were area under the curve between dosing and 168 h (AUC0-168 h ) and the maximum plasma concentration (Cmax )., Results: There was no clinically relevant difference between subjects with severe renal impairment/ESRD and normal renal function with respect to total exposure (AUC0-168 h ) and peak plasma concentrations (Cmax ) of glepaglutide following a single SC dose. A single SC dose of glepaglutide 10 mg appeared safe and well tolerated in subjects with normal renal function and subjects with severe renal impairment or ESRD. No serious adverse events were reported, and no safety issues were identified., Conclusions: No difference in glepaglutide pharmacokinetics was seen between renal impaired and normal subjects. Based on this trial, dose adjustment appears not to be warranted in SBS patients with renal impairment., Trial Registration: The trial is registered at http://www., Clinicaltrials: gov (NCT04178447) and has the EudraCT number: 2019-001466-15., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
36. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
- Author
-
Csiky B, Schömig M, Esposito C, Barratt J, Reusch M, Valluri U, and Sulowicz W
- Subjects
- Glycine analogs & derivatives, Hemoglobins analysis, Humans, Isoquinolines, Renal Dialysis, Research Design, Anemia drug therapy, Anemia etiology, Hematinics therapeutic use, Kidney Failure, Chronic, Renal Insufficiency, Chronic complications
- Abstract
Introduction: Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This European, phase 3, randomized, open-label, active-controlled study investigated efficacy and safety of roxadustat in patients with end-stage kidney disease on dialysis for at least 4 months., Methods: Patients were randomized to switch from an erythropoiesis-stimulating agent (ESA) (epoetin alfa or darbepoetin alfa) to roxadustat three times/week or to continue their previous ESA. Roxadustat and ESA doses were adjusted to maintain hemoglobin within 10.0-12.0 g/dL during the treatment period (day 1 up to 52-104 weeks). Primary endpoints were hemoglobin change from baseline (CFB) to the average of weeks 28-36 without rescue therapy and hemoglobin CFB to the average of weeks 28-52 regardless of rescue therapy. Treatment-emergent adverse events (TEAEs) were assessed descriptively., Results: Of 1081 screened patients, 836 were randomized and received treatment (roxadustat, n = 415; ESA, n = 421). The least squares means (95% CI) of the treatment difference (roxadustat - ESA) for hemoglobin CFB to weeks 28-36 (without rescue therapy) and CFB to weeks 28-52 (regardless of rescue therapy) were 0.235 (0.132, 0.339) g/dL and 0.171 (0.082, 0.261) g/dL, respectively, demonstrating non-inferiority of roxadustat to ESA (non-inferiority margin of - 0.75 g/dL). The proportions of patients who achieved target hemoglobin without rescue therapy during weeks 28-36 were 84.2% (roxadustat) and 82.4% (ESA). Roxadustat was superior to ESA in decreasing LDL cholesterol from baseline to the average of weeks 12-28. Serious TEAEs occurred in 50.7% (roxadustat) and 45.0% (ESA) of patients. Common TEAEs in both treatment groups included hypertension, arteriovenous fistula thrombosis, headache, and diarrhea., Conclusion: Roxadustat was non-inferior to ESAs in maintaining hemoglobin levels in this cohort of patients with anemia of CKD on dialysis for at least 4 months who were previously treated with ESAs. Observed TEAEs were consistent with previous studies., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
37. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
- Author
-
Barratt J, Sulowicz W, Schömig M, Esposito C, Reusch M, Young J, and Csiky B
- Subjects
- Glycine adverse effects, Glycine analogs & derivatives, Hemoglobins, Humans, Isoquinolines adverse effects, Renal Dialysis, Erythropoietin, Hematinics, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic therapy
- Abstract
Introduction: This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients., Methods: Efficacy and safety results from four phase 3, randomized, open-label studies comparing roxadustat to ESAs (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES) in dialysis-dependent patients with anemia of chronic kidney disease (CKD) were evaluated by study, pooled population and in two subgroups: incident dialysis and stable dialysis. The primary efficacy endpoint per study was hemoglobin change from baseline (CFB) to weeks 28-36 using least-squares mean difference (LSMD) without rescue therapy. Pooled safety endpoints included time to major adverse cardiovascular event (MACE; myocardial infarction, stroke, and all-cause mortality [ACM]) and MACE+ (MACE plus congestive heart failure or unstable angina requiring hospitalization), ACM, and treatment-emergent adverse events (TEAEs). MACE and MACE+ were evaluated for non-inferiority at 1.8 and 1.3 margins using hazard ratios (HRs) and 95% confidence intervals (CIs). TEAEs were descriptively summarized., Results: In total, 4714 patients were randomized (2354 roxadustat; 2360 ESA). Hemoglobin CFB to weeks 28-36 achieved non-inferiority for roxadustat vs ESA in each study. Roxadustat was non-inferior to ESA for risks for MACE and MACE+ in the entire cohort (MACE: HR 1.09, 95% CI 0.95-1.26; MACE+ : HR 0.98, 95% CI 0.86-1.11) and similar to the incident dialysis and stable dialysis subgroups; ACM results were consistent with MACE and MACE+ (HR 1.13, 95% CI 0.95-1.34). TEAEs were generally comparable between groups., Conclusion: Roxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
38. Clinicopathologic correlations of renal pathology in the adult population of Poland.
- Author
-
Perkowska-Ptasinska A, Bartczak A, Wagrowska-Danilewicz M, Halon A, Okon K, Wozniak A, Danilewicz M, Karkoszka H, Marszalek A, Kowalewska J, Mroz A, Korolczuk A, Oko A, Debska-Slizien A, Naumnik B, Hruby Z, Klinger M, Ciechanowski K, Myslak M, Sulowicz W, Rydzewski A, Wiecek A, Manitius J, Gregorczyk T, Niemczyk S, Nowicki M, Gellert R, Stompor T, Wieliczko M, Marczewski K, Paczek L, Rostkowska O, Deborska-Materkowska D, Bogdanowicz G, Milkowski A, and Durlik M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biopsy, Child, Child, Preschool, Female, Humans, Infant, Kidney Diseases epidemiology, Male, Middle Aged, Poland epidemiology, Prospective Studies, Registries, Sex Distribution, Young Adult, Kidney pathology, Kidney Diseases pathology
- Abstract
Background: This is the first report on the epidemiology of biopsy-proven kidney diseases in Poland., Methods: The Polish Registry of Renal Biopsies has collected information on all (n = 9394) native renal biopsies performed in Poland from 2009 to 2014. Patients' clinical data collected at the time of biopsy, and histopathological diagnoses were used for epidemiological and clinicopathologic analysis., Results: There was a gradual increase in the number of native renal biopsies performed per million people (PMP) per year in Poland in 2009-14, starting from 36 PMP in 2009 to 44 PMP in 2014. A considerable variability between provinces in the mean number of biopsies performed in the period covered was found, ranging from 5 to 77 PMP/year. The most common renal biopsy diagnoses in adults were immunoglobulin A nephropathy (IgAN) (20%), focal segmental glomerulosclerosis (FSGS) (15%) and membranous glomerulonephritis (MGN) (11%), whereas in children, minimal change disease (22%), IgAN (20%) and FSGS (10%) were dominant. Due to insufficient data on the paediatric population, the clinicopathologic analysis was limited to patients ≥18 years of age. At the time of renal biopsy, the majority of adult patients presented nephrotic-range proteinuria (45.2%), followed by urinary abnormalities (38.3%), nephritic syndrome (13.8%) and isolated haematuria (1.7%). Among nephrotic patients, primary glomerulopathies dominated (67.6% in those 18-64 years of age and 62.4% in elderly patients) with leading diagnoses being MGN (17.1%), FSGS (16.2%) and IgAN (13.0%) in the younger cohort and MGN (23.5%), amyloidosis (18.8%) and FSGS (16.8%) in the elderly cohort. Among nephritic patients 18-64 years of age, the majority (55.9%) suffered from primary glomerulopathies, with a predominance of IgAN (31.3%), FSGS (12.7%) and crescentic GN (CGN) (11.1%). Among elderly nephritic patients, primary and secondary glomerulopathies were equally common (41.9% each) and pauci-immune GN (24.7%), CGN (20.4%) and IgAN (14.0%) were predominant. In both adult cohorts, urinary abnormalities were mostly related to primary glomerulopathies (66.8% in younger and 50% in elderly patients) and the leading diagnoses were IgAN (31.4%), FSGS (15.9%), lupus nephritis (10.7%) and FSGS (19.2%), MGN (15.1%) and pauci-immune GN (12.3%), respectively. There were significant differences in clinical characteristics and renal biopsy findings between male and female adult patients., Conclusions: The registry data focused new light on the epidemiology of kidney diseases in Poland. These data should be used in future follow-up and prospective studies., (© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
39. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients.
- Author
-
Massart A, Pallier A, Pascual J, Viklicky O, Budde K, Spasovski G, Klinger M, Sever MS, Sørensen SS, Hadaya K, Oberbauer R, Dudley C, De Fijter JW, Yussim A, Hazzan M, Wekerle T, Berglund D, De Biase C, Pérez-Sáez MJ, Mühlfeld A, Orlando G, Clemente K, Lai Q, Pisani F, Kandus A, Baas M, Bemelman F, Ponikvar JB, Mazouz H, Stratta P, Subra JF, Villemain F, Hoitsma A, Braun L, Cantarell MC, Colak H, Courtney A, Frasca GM, Howse M, Naesens M, Reischig T, Serón D, Seyahi N, Tugmen C, Alonso Hernandez A, Beňa L, Biancone L, Cuna V, Díaz-Corte C, Dufay A, Gaasbeek A, Garnier A, Gatault P, Gentil Govantes MA, Glowacki F, Gross O, Hurault de Ligny B, Huynh-Do U, Janbon B, Jiménez Del Cerro LA, Keller F, La Manna G, Lauzurica R, Le Monies De Sagazan H, Thaiss F, Legendre C, Martin S, Moal MC, Noël C, Pillebout E, Piredda GB, Puga AR, Sulowicz W, Tuglular S, Prokopova M, Chesneau M, Le Moine A, Guérif P, Soulillou JP, Abramowicz M, Giral M, Racapé J, Maggiore U, Brouard S, and Abramowicz D
- Subjects
- Adult, Europe epidemiology, Female, Graft Rejection immunology, Graft Rejection prevention & control, Humans, Incidence, Male, Surveys and Questionnaires, Survival Rate trends, Transplantation, Homologous, Graft Rejection epidemiology, Graft Survival immunology, Immune Tolerance immunology, Immunosuppression Therapy methods, Kidney Transplantation, Transplant Recipients
- Abstract
Background: Kidney recipients maintaining a prolonged allograft survival in the absence of immunosuppressive drugs and without evidence of rejection are supposed to be exceptional. The ERA-EDTA-DESCARTES working group together with Nantes University launched a European-wide survey to identify new patients, describe them and estimate their frequency for the first time., Methods: Seventeen coordinators distributed a questionnaire in 256 transplant centres and 28 countries in order to report as many 'operationally tolerant' patients (TOL; defined as having a serum creatinine <1.7 mg/dL and proteinuria <1 g/day or g/g creatinine despite at least 1 year without any immunosuppressive drug) and 'almost tolerant' patients (minimally immunosuppressed patients (MIS) receiving low-dose steroids) as possible. We reported their number and the total number of kidney transplants performed at each centre to calculate their frequency., Results: One hundred and forty-seven questionnaires were returned and we identified 66 TOL (61 with complete data) and 34 MIS patients. Of the 61 TOL patients, 26 were previously described by the Nantes group and 35 new patients are presented here. Most of them were noncompliant patients. At data collection, 31/35 patients were alive and 22/31 still operationally tolerant. For the remaining 9/31, 2 were restarted on immunosuppressive drugs and 7 had rising creatinine of whom 3 resumed dialysis. Considering all patients, 10-year death-censored graft survival post-immunosuppression weaning reached 85% in TOL patients and 100% in MIS patients. With 218 913 kidney recipients surveyed, cumulative incidences of operational tolerance and almost tolerance were estimated at 3 and 1.5 per 10 000 kidney recipients, respectively., Conclusions: In kidney transplantation, operational tolerance and almost tolerance are infrequent findings associated with excellent long-term death-censored graft survival., (© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
40. Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients.
- Author
-
Opalinska M, Stompor T, Pach D, Mikolajczak R, Fedak D, Krzanowski M, Rakowski T, Sowa-Staszczak A, Glowa B, Garnuszek P, Maurin M, Karczmarczyk U, Sulowicz W, and Hubalewska-Dydejczyk A
- Subjects
- Biological Transport, Carotid Arteries metabolism, Female, Hemoglobins metabolism, Humans, Inflammation diagnostic imaging, Male, Middle Aged, Plaque, Atherosclerotic metabolism, Radionuclide Imaging, Risk, Carotid Arteries diagnostic imaging, Interleukin-12 metabolism, Kidney Failure, Chronic complications, Organotechnetium Compounds metabolism, Plaque, Atherosclerotic complications, Plaque, Atherosclerotic diagnostic imaging
- Abstract
Purpose: Identification of vulnerable plaques remains crucial for better cardiovascular risk assessment. At least 20% of inflammatory cells within unstable (vulnerable) plaques comprise T lymphocytes, which contain receptors for interleukin-2 (IL-2); those receptors can be identified by scintigraphy with radiolabelled IL-2.The aim of this study was to identify the "inflamed" (vulnerable) plaques by scintigraphy using IL-2 labelled with (99m)Tc in the selected, high cardiovascular risk group of end-stage renal disease (ESRD) patients., Methods: A total of 28 patients (18 men, 10 women, aged 55.2 ± 9.6 years, 17 on peritoneal dialysis, 11 on haemodialysis) underwent common carotid artery (CCA) scintigraphy with the use of (99m)Tc-hydrazinonicotinamide (HYNIC)-IL-2. In all cases, ultrasound examination of the CCA was performed and levels of selected proinflammatory factors, atherogenic markers and calcium-phosphate balance parameters were measured. Finally, the target to non-target (T/nT) ratio of IL-2 uptake in atherosclerotic plaques with intima-media thickness (IMT), classic cardiovascular risk factors and concentrations of the measured factors were compared., Results: Increased (99m)Tc-HYNIC-IL-2 uptake in atherosclerotic plaques in 38/41 (91%) cases was detected. The median T/nT ratio of focal (99m)Tc-HYNIC-IL-2 uptake in atherosclerotic plaques was 2.35 (range 1.23-3.63). The mean IMT value on the side of plaques assessed by scintigraphy was 0.79 ± 0.18 mm (median 0.8, range 0.5-1.275). Correlations between T/nT ratio and homocysteine (R = 0.22, p = 0.037), apolipoprotein B (apoB) (R = 0.31, p = 0.008), apoB to apoA-I ratio (R = 0.29, p = 0.012) and triglyceride concentration (R = 0.26, p = 0.021) were detected. A lower T/nT ratio in patients with better parameters of nutritional status (haemoglobin, albumin, adiponectin) in comparison with patients with worse nutritional parameters (3.20 ± 0.5 vs 2.16 ± 0.68, p = 0.025) was revealed as well as a difference between values of T/nT ratio in groups of patients with values of apoB, soluble CD40 ligand and asymmetric dimethylarginine above and below median (3.18 ± 0.52 vs 2.16 ± 0.68, p = 0.031). No statistically significant association was found between T/nT ratio and mean value of either IMT or classic cardiovascular risk factors., Conclusion: Scintigraphy with the use of (99m)Tc-HYNIC-IL-2 can be a tool for inflamed atherosclerotic (vulnerable) plaque visualization within CCA in ESRD patients. Quantitative results of carotid artery scintigraphy with (99m)Tc-HYNIC-IL-2 correlate with serum concentration of selected cardiovascular risk markers.
- Published
- 2012
- Full Text
- View/download PDF
41. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.
- Author
-
Cawello W, Ahrweiler S, Sulowicz W, Szymczakiewicz-Multanowska A, and Braun M
- Subjects
- Adult, Aged, Area Under Curve, Case-Control Studies, Dopamine Agonists administration & dosage, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Tetrahydronaphthalenes administration & dosage, Thiophenes administration & dosage, Dopamine Agonists pharmacokinetics, Renal Insufficiency metabolism, Tetrahydronaphthalenes pharmacokinetics, Thiophenes pharmacokinetics, Transdermal Patch
- Abstract
Aim: To evaluate the influence of different stages of chronic renal insufficiency on the pharmacokinetics and safety/tolerability of the transdermally applied dopamine agonist rotigotine in an open label group comparison including 32 subjects (healthy, mild, moderate or severe impairment of renal function and patients with end-stage renal insufficiency requiring haemodialysis). METHODS All subjects received a single transdermal 10 cm² patch (24 h patch-on period) containing 4.5 mg rotigotine (nominal drug release 2 mg 24 h⁻¹). Main evaluations included relative bioavailability and renal elimination of rotigotine and its metabolites., Results: Point estimates for the ratios between the groups with moderate to severe renal impairment and healthy subjects for the pharmacokinetic parameters AUC(0,t(last) ) and C(max) for the active substance unconjugated rotigotine were near 1:0.88 for AUC and 0.93 for C(max) for moderate renal impairment, 1.14 and 1.18 for severe renal impairment and 1.05 and 1.25 for end-stage renal insufficiency requiring haemodialysis. There was no correlation of these parameters with creatinine clearance. The amount of unconjugated rotigotine excreted into urine and renal clearance decreased with increasing severity of renal insufficiency but had no observable effect on total clearance as the amounts excreted were below 1% of the administered dose. Occurrence of adverse events did not increase with the degree of renal insufficiency., Conclusions: The pharmacokinetic profiles of unconjugated rotigotine were similar in healthy subjects and subjects with impaired renal function indicating that no dose adjustments are required for transdermal rotigotine in patients with different stages of chronic renal insufficiency including patients on haemodialysis., (© 2011 UCB Biosciences GmbH. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.)
- Published
- 2012
- Full Text
- View/download PDF
42. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease.
- Author
-
Locatelli F, Mann JF, Aldigier JC, Sanz Guajardo D, Schmidt R, Van Vlem B, Sulowicz W, Dougherty FC, and Beyer U
- Subjects
- Anemia epidemiology, Anemia etiology, Dose-Response Relationship, Drug, Erythropoietin administration & dosage, Follow-Up Studies, Humans, Incidence, Kidney Failure, Chronic therapy, Polyethylene Glycols administration & dosage, Prospective Studies, Recombinant Proteins, Renal Dialysis, Time Factors, Treatment Outcome, Anemia drug therapy, Erythropoietin therapeutic use, Kidney Failure, Chronic complications, Polyethylene Glycols therapeutic use
- Abstract
Background: C.E.R.A., a continuous erythropoietin receptor activator, is a long-acting erythropoiesis-stimulating agent (ESA) that is approved for the treatment of renal anemia. This analysis evaluated the safety profile of C.E.R.A. in comparison to that of other ESAs in patients with chronic kidney disease (CKD)., Methods: Safety parameters were analyzed in a pooled population comprising all patients with CKD on dialysis and not on dialysis from the completed Phase II and Phase III studies in the C.E.R.A. clinical program (Phase II/III population); patients were treated with either C.E.R.A. (n = 1,789) or comparator ESA (n = 948). Differences between treatment groups in safety parameters were identified by either a 2% difference in incidence between groups, or a statistically significant difference between groups (p < or = 0.05 with the Fisher's exact test, which was used as a conservative screening tool). To assess changes in safety findings over time, long-term safety data were analyzed from patients who were given the option to enter long-term safety studies upon completing their initial Phase II/III study (safety extension population)., Results: Compared with the C.E.R.A. group, the incidence of adverse events (AEs) was higher in the comparator ESA group in the Phase II/III population (C.E.R.A. vs. comparator ESA, 89.5% vs. 91.8%, p = 0.067), and significantly so in the safety extension population (93.0% vs. 95.8%, p = 0.003). The incidence of serious AEs was significantly higher in the comparator ESA group than in the C.E.R.A. group in both analysis populations (Phase II/III population, 37.8% vs. 42.4%, p = 0.021; safety extension population, 53.3% vs. 59.7%, p = 0.001). However, there was no consistent pattern of clinical events that could explain these differences between the treatment groups., Conclusion: Analysis of safety events in patients with renal anemia receiving long-term treatment with C.E.R.A. shows a safety profile comparable to that of other ESAs.
- Published
- 2010
- Full Text
- View/download PDF
43. [Kaposi's sarkoma in solid organ recipients].
- Author
-
Betkowska-Prokop A, Sułowicz J, Sobaszek-Pitas M, and Sulowicz W
- Subjects
- Humans, Immunocompromised Host, Sarcoma, Kaposi diagnosis, Organ Transplantation adverse effects, Sarcoma, Kaposi immunology, Sarcoma, Kaposi therapy, Transplants adverse effects
- Abstract
Kaposi's sarkoma (KS) is a malignancy with hyperplastic angio-proliferative lesions with inflammatory changes usually associated with human Herpesvirus 8 (HHV-8) infection. The predominant is skin localization with dark-blue or purplish colour nodules and plaques. Cutaneous changes may be associated with visceral involvement, which as a isolated form is rare. KS is not frequent disease in general population however risk of its development is substantially increased in immunocompromised patients including AIDS or receiving immunosuppression transplant organ recipients. The potency of immunosuppression is a highly relevant factor in the development of KS after transplantation. Patients receiving more intense immunosuppression are at a significantly higher risk of developing post transplant KS. Localized disease may be treated by surgery, kriotherapy or radiotherapy while widespread envolvement usually needs systemic therapy. Reduction or cessation of immunosuppression, especially calcineurin inhibitors, in transplant organs recipients gives positive therapeutic results. Swich from calcineurin inhibitors to rapamycin, immunosuppressive agent with anti-neoplastic activity, is a novel therapeutic option for solid rorgans recipients.
- Published
- 2010
44. Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study.
- Author
-
Hubalewska-Dydejczyk A, Stompór T, Kalembkiewicz M, Krzanowski M, Mikolajczak R, Sowa-Staszczak A, Tabor-Ciepiela B, Karczmarczyk U, Kusnierz-Cabala B, and Sulowicz W
- Subjects
- Carotid Artery Diseases complications, Carotid Stenosis complications, Carotid Stenosis diagnostic imaging, Female, Humans, Inflammation, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Male, Middle Aged, Radionuclide Imaging, Risk Factors, Carotid Artery Diseases diagnostic imaging, Carotid Artery, Common diagnostic imaging, Interleukin-2, Iodine Radioisotopes, Peritoneal Dialysis
- Abstract
Background: Patients with end-stage renal disease (ESRD) suffer from markedly increased cardiovascular morbidity and mortality. Common carotid artery (CCA) intima-media thickness (IMT) assessment and CCA plaque identification using ultrasound are well-recognized tools for identification and monitoring of atherosclerosis. A new method for monitoring the inflammatory status of plaque, namely radiolabeled interleukin-2 (IL-2) scintigraphy, was proposed recently. The aim of this pilot study was to perform (123)I-labeled-IL-2 carotid plaque scintigraphy in ESRD patients treated with peritoneal dialysis and to correlate obtained results with ultrasound assessment of CCA and selected inflammatory markers., Methods: CCA-IMT was measured and CCA plaques were identified by ultrasound in 10 patients (5 women, 5 men; mean age 62.4 +/- 10.4 years; median peritoneal dialysis duration 32.5 months, range 12 - 55 months) with advanced cardiovascular comorbidity. Following CCA ultrasound, (123)I-labeled IL-2 carotid plaque scintigraphy was performed. Several biomarkers of inflammation and atherosclerosis were also measured in all patients., Results: Mean target/non-target ratio for focal (123)I-IL-2 uptake within the plaque was 3.15 +/- 0.54, and mean IMT from the site of the scintigraphy analysis was 0.975 +/- 0.337 mm. Highly significant correlation was found between CCA-IMT and a target/non-target ratio for focal (123)I-IL-2 uptake in a corresponding artery (R = 0.92, p = 0.01). However, no significant correlations were found between target/non-target ratio for focal (123)I-IL-2 uptake and levels of measured biomarkers., Conclusions: Our preliminary results suggest potential for identification of an inflamed (vulnerable) plaque using IL-2 scintigraphy in ESRD patients with cardiovascular comorbidities.
- Published
- 2009
45. Two consecutive cases of renal oncocytomatosis in a single-center experience.
- Author
-
Sydor A, Sulowicz W, Stompór T, Plezia B, Wrona A, and Okon K
- Subjects
- Adenoma, Oxyphilic parasitology, Aged, Aged, 80 and over, Comorbidity, Diagnosis, Differential, Fatal Outcome, Female, Humans, Kidney Neoplasms pathology, Male, Neoplasms, Multiple Primary pathology, Adenoma, Oxyphilic diagnosis, Kidney Neoplasms diagnosis, Neoplasms, Multiple Primary diagnosis
- Abstract
Renal oncocytoma is a rare finding and represents the small percentage of all kidney tumors. This kind of tumor is benign and diagnosed accidentally (on autopsy or during nephrectomy performed for other reasons). On rare occasions, truly multiple tumors are seen, affecting the entire renal parenchyma; this condition is called oncocytosis or oncocytomatosis. Here we present two cases of this condition, diagnosed consecutively in a single internal medicine department.
- Published
- 2009
- Full Text
- View/download PDF
46. Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease.
- Author
-
Przewlocki T, Kablak-Ziembicka A, Tracz W, Kopec G, Rubis P, Pasowicz M, Musialek P, Kostkiewicz M, Kozanecki A, Stompór T, Sulowicz W, and Sokolowski A
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Logistic Models, Male, Middle Aged, Prevalence, Prognosis, Radiography, Regression Analysis, Renal Artery Obstruction diagnostic imaging, Aortic Stenosis, Supravalvular complications, Coronary Artery Disease complications, Renal Artery Obstruction epidemiology
- Abstract
Background: Renal atherosclerosis is associated with increased cardiovascular mortality. This study aimed to determine the prevalence and predictors of renal artery stenosis (RAS) in patients with coronary artery disease (CAD) and supraaortic arteries (SA) stenosis., Methods: Renal angiography was performed in 1193 (807 men) consecutive patients referred for coronary or SA angiography. Group I included 296 (136 men, 60.1 +/- 9.5 years) patients with no significant (< 50%) lesion in coronary arteries or SA; group II included 706 (526 men, 62.2 +/- 9.7 years) patients with stenosis > or = 50% within single arterial territory (coronary arteries or SA) and group III included 191 (145 men, 64.9 +/- 8.5 years) patients with stenosis > or = 50% in both territories., Results: Some RAS was found in 55 (18.6%) patients in group I, 250 (35.4%) patients in group II and 115 (60.2%) patients in group III (P < 0.001). The proportion of patients with RAS > or = 50% in groups I, II and III was 3.3, 6.2 and 18.3%, respectively (P < 0.001). RAS prevalence increased with the number of stenosed coronary arteries (38.4% in 1-vessel, 42.1% in 2-vessel, 48.5% in 3-vessel CAD, P < 0.001). Independent predictors of RAS > or = 50% identified by logistic regression analysis were SA stenosis [relative risk (RR) = 3.28, P < 0.001], 2-3-vessel-CAD (RR = 2.04, P = 0.002), creatinine level > or = 1.07 mg/dl (RR = 2.95, P < 0.001), hypertension (RR = 2.97, P = 0.012) and body mass index < 25 kg/m(2) (RR = 1.42, P = 0.169). A calculated score for RAS > or = 50% prediction (based on the regression model) was reliable (coefficient of determination, R = 0.978) and showed a sensitivity of 77.5% and a specificity of 63.9%., Conclusions: RAS prevalence and severity increases with the number of arterial territories involved and CAD severity. The following independent predictors of RAS > or = 50% were identified: SA involvement, 2-3-vessel-CAD, serum creatinine level and hypertension.
- Published
- 2008
- Full Text
- View/download PDF
47. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
- Author
-
Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, and Beyer U
- Subjects
- Anemia etiology, Anemia metabolism, Dose-Response Relationship, Drug, Drug Carriers adverse effects, Erythropoietin adverse effects, Female, Hemoglobins metabolism, Humans, Hypertension chemically induced, Male, Middle Aged, Peritoneal Dialysis adverse effects, Polyethylene Glycols adverse effects, Recombinant Proteins, Renal Dialysis adverse effects, Thrombosis chemically induced, Treatment Outcome, Anemia drug therapy, Drug Carriers therapeutic use, Erythropoietin therapeutic use, Polyethylene Glycols therapeutic use
- Abstract
Background: C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, was developed to provide stable control of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease. We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent-naive dialysis patients., Study Design: Open-label, multicenter, randomized, parallel-group, phase 3 study., Setting & Participants: Dialysis patients (age >or= 18 years)., Intervention: Patients (n = 181) were randomly assigned (3:1) to receive intravenous C.E.R.A. once every 2 weeks or epoetin 3 times weekly., Outcomes & Measurements: The primary end point was Hb level response rate (increase in Hb level >or= 1 g/dL [10 g/L] versus baseline and Hb level >or= 11 g/dL [110 g/L] without blood transfusion during the 24-week correction period) in the intent-to-treat population., Results: Hb response rates (intent-to-treat population) were 93.3% with C.E.R.A. and 91.3% with epoetin. Similar results were found in the per-protocol population. Peak mean Hb levels were 12.28 +/- 1.13 (SD) g/dL (122.8 +/- 11.3 g/L) with C.E.R.A. and 12.19 +/- 1.24 g/dL (121.9 +/- 12.4 g/L) with epoetin. Mean change in Hb levels from baseline to the end of the correction period were 2.70 +/- 1.45 g/dL (27 +/- 14.5 g/L) with C.E.R.A. and 2.56 +/- 1.31 g/dL (25.6 +/- 13.1 g/L) with epoetin. Both treatments were generally well tolerated., Limitations: Open-label study design, 3:1 randomization, limited peritoneal dialysis population, descriptive statistics, and lack of formal prespecified comparison to epoetin., Conclusions: Intravenous C.E.R.A. once every 2 weeks may be as safe and effective as 3-times-weekly epoetin for correcting anemia in dialysis patients. These results show the utility of intravenous C.E.R.A. administered once every 2 weeks in erythropoiesis-stimulating agent-naive dialysis patients.
- Published
- 2007
- Full Text
- View/download PDF
48. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
- Author
-
Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, and Beyer U
- Subjects
- Anemia etiology, Chronic Disease, Drug Administration Schedule, Epoetin Alfa, Female, Humans, Injections, Subcutaneous, Kidney Diseases complications, Male, Middle Aged, Recombinant Proteins, Anemia blood, Anemia drug therapy, Erythropoietin administration & dosage, Erythropoietin therapeutic use, Hematinics therapeutic use, Hemoglobins analysis, Kidney Diseases blood, Polyethylene Glycols administration & dosage, Renal Dialysis
- Abstract
Background: C.E.R.A., a continuous erythropoietin receptor activator, is in development to provide anemia correction and stable maintenance of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease (CKD). This study examined its efficacy and safety when administered up to once monthly in patients who have CKD and are on dialysis and randomly convert directly from epoetin alpha or beta one to three times weekly., Design, Setting, Participants, and Measurements: In this three-arm, comparator-controlled, open-label, randomized, parallel-group, Phase III study, 572 dialysis patients (> or =18 yr) who were receiving stable subcutaneous epoetin one to three times weekly were randomly assigned (1:1:1) to continue epoetin or to receive subcutaneous C.E.R.A. once monthly or twice monthly for 52 wk. Dosage was adjusted to maintain Hb +/-1.0 g/dl of baseline level. Primary end point was mean change in Hb level between baseline and the evaluation period (weeks 29 to 36)., Results: Mean Hb levels during the evaluation period were similar between groups (once-monthly C.E.R.A. 11.5 g/dl; twice-monthly C.E.R.A. 11.7 g/dl; epoetin 11.5 g/dl). The difference between C.E.R.A. and epoetin in mean change (97.5% confidence interval) in Hb concentration between baseline and evaluation was -0.022 g/dl (-0.262 to 0.217) for once monthly and 0.141 g/dl (-0.098 to 0.380) for twice monthly. Analysis demonstrated that C.E.R.A. was as effective as epoetin in maintaining Hb and was well tolerated., Conclusions: Subcutaneous C.E.R.A. once or twice monthly successfully maintained tight and stable Hb levels in patients who were on dialysis and randomly converted directly from epoetin one to three times weekly.
- Published
- 2007
- Full Text
- View/download PDF
49. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk.
- Author
-
Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, and El Nahas M
- Subjects
- Double-Blind Method, Humans, Middle Aged, Risk Factors, Cardiovascular Diseases prevention & control, Human Growth Hormone therapeutic use, Nutritional Status, Quality of Life, Renal Dialysis
- Abstract
Nutritional markers, such as lean body mass (LBM) and serum albumin, predict outcome in dialysis patients, in whom protein-energy malnutrition is associated with increased morbidity and mortality. The metabolic effects of human growth hormone (hGH) may improve the nutritional and cardiovascular health of these patients and consequently reduce morbidity and mortality. The aim of this study was to establish clinical proof of concept of hGH treatment for the improvement of the nutritional status in adult patients who are on maintenance hemodialysis. A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH. Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored. The study showed that hGH treatment increased LBM significantly at all dosage levels (2.5 kg [95% confidence interval 1.8 to 3.1] versus -0.4 kg [95% confidence interval -1.4 to 0.6]; P < 0.001 for pooled hGH groups versus placebo). Serum albumin tended to increase (P = 0.076), serum transferrin (P = 0.001) and serum HDL (P < 0.038) increased, and plasma homocysteine was reduced (P = 0.029). TNF-alpha also tended to decrease with treatment (P = 0.134). An improvement in the Role Physical SF-36 quality-of-life subscale was observed (P = 0.042). There were no differences in clinically relevant adverse events between groups. In conclusion, hGH therapy safely improves LBM, other markers of mortality and morbidity, and health-related quality of life in adult patients who are on maintenance hemodialysis. A long-term study is warranted to investigate whether these treatment benefits result in reduced mortality and morbidity.
- Published
- 2007
- Full Text
- View/download PDF
50. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
- Author
-
Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, and Dougherty FC
- Subjects
- Adult, Aged, Aged, 80 and over, Analysis of Variance, Area Under Curve, Biomarkers blood, Dose-Response Relationship, Drug, Erythropoiesis drug effects, Erythropoietin adverse effects, Erythropoietin blood, Female, Ferritins blood, Ferritins drug effects, Follow-Up Studies, Hemoglobins drug effects, Humans, Male, Middle Aged, Polyethylene Glycols adverse effects, Recombinant Proteins, Regression Analysis, Time Factors, Treatment Outcome, Anemia drug therapy, Anemia etiology, Erythropoietin administration & dosage, Kidney Failure, Chronic complications, Polyethylene Glycols administration & dosage, Renal Dialysis
- Abstract
Aim: This study was designed to assess the potential of the continuous erythropoietin receptor activator (C.E.R.A.) to correct anemia at extended administration intervals in erythropoiesis-stimulating agent-naīve patients with chronic kidney disease (CKD) not on dialysis and to determine its optimal starting dose., Methods: Patients were assigned to subcutaneous C.E.R.A. at 3 doses: 0.15, 0.30 and 0.60 microg/kg/wk. During the first 6 weeks, dose adjustments for efficacy were not permitted in order to assess dose response. Within each of the 3 dose groups, patients were randomized to receive C.E.R.A. QW, Q2W or Q3W; the total dose during the first 6 weeks was the same for a particular dose group across the frequency subgroups. During the next 12 weeks, dose was adjusted according to predefined hemoglobin (Hb) criteria. The primary efficacy parameter was change in Hb over 6 weeks, estimated from regression analysis between baseline and the point at which the patient received a dose change or blood transfusion. It therefore provided an estimate of Hb increase based on starting dose. Other endpoints included Hb response rate (proportion of patients with a Hb increase > 1.0 g/dl on 2 consecutive occasions). A 1-year extension period investigated long term tolerability and efficacy., Results: A dose-dependent relationship was noted in the mean change in Hb from baseline over 6 weeks (p < 0.0001), independent of administration schedule (p = 0.9201). There was also a significant relationship between Hb change and median serum C.E.R.A. concentration (p < 0.0001). Erythropoietic responses were sustained in all groups with mean changes from baseline in Hb > 1.2 g/dl observed at doses > or = 0.30 microg/kg/wk. Hb response rate increased with increasing dose: 67, 72 and 90% with C.E.R.A. 0.15, 0.30 and 0.60 microg/kg/wk, respectively. Generally, the median Hb response time was faster with increasing dose (89, 43 and 31 days, respectively). Response was unrelated to administration frequency. Stable Hb concentrations were maintained throughout the 1-year extension period. C.E.R.A. was generally well tolerated, and the most common adverse events were hypertension, urinary tract infection and renal failure., Conclusions: C.E.R.A. corrected anemia and maintained sustained and stable control of Hb over 1 year. These results suggest that 0.60 microg/kg subcutaneous C.E.R.A. given twice monthly is a suitable starting dose for further investigation in Phase III studies in patients with CKD not on dialysis.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.